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ABSTRACT 
 
   Breast cancer is the second most common cancer globally and accounts for the 
highest morbidity and mortality. Although anti-estrogens have provided an effective 
endocrine therapy, a significant proportion of patients have acquired resistance to 
these drugs. In addition, due to high levels of toxicity associated with nuclear 
hormone receptor, Peroxisome Proliferator-Activated Receptor gamma (PPARγ) 
agonists - Thiazolidinediones (TZDs) (e.g. - troglitazone (Rezulin), rosiglitazone 
(Avandia), and pioglitazone (Actos)), and their recent withdrawal in several 
countries, there is a requirement for alternative therapeutics, such development of 
new PPAR drugs to treat breast cancer that exhibit better efficacy but lesser toxicity. 
PPARγ agonist’s role in inhibiting breast cancer is well known, however their role in 
cellular bioenergetics of cancer still needs to be explored. Taking into account, the 
PPARγ over-expression in breast cancer, this study focuses on the computational 
identification of PPARγ metabolic targets and validating their modulation by PPARγ 
natural and novel ligands as therapeutic targets of PPARγ involved in breast cancer 
pathophysiology. 
Computational identification and validation of novel transcriptional targets 
of PPARγ involved in breast cancer pathophysiology 
     In this study, I carried out prediction of the PPARγ binding motifs - peroxisome 
proliferator response element (PPRE) and PPAR-associated conserved motif 
(PACM) in 2332 genes reported to be involved in breast cancer in literature. A total 
of 218 genes were found to have PPRE (DR1/DR2) and / or PACM motifs. I further 
constructed protein-protein interaction network, disease gene network and gene 
ontology (GO) analyses to identify novel key genes for experimental validation. I 
identified two novel PPARγ target genes in the glycolytic pathway 
(phosphoglycerate kinase 1 (PGK1) and pyruvate kinase M2 (PKM2)) at the ATP 
production steps and experimentally validated their repression by PPARγ activation 
in two breast cancer cell lines - MDA-MB-231 and MCF-7 by PPARγ natural ligand, 
15-Deoxy-Delta12, 14-Prostaglandin J2 (15d-PGJ2). Further analysis suggested that 
this repression leads to decrease in ATP levels and apoptosis in breast cancer cell 
lines.  
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Identification and functional validation of the putative PPARγ ligand – Coffee 
component Hydroxyl Hydroquinone (HHQ). 
In this study, I prospectively investigated whether coffee component HHQ is a 
potential PPARγ ligand and its modulatory effects on glycolytic and pro-apoptotic 
genes via PPARγ dependent pathway in breast cancer cells. In this study, HHQ was 
confirmed as ligand for PPARγ by docking procedure. Further analysis suggested 
that HHQ also had significant apoptotic effect as well as down regulation of 
glycolytic genes phosphoglycerate kinase 1 (PGK1) and pyruvate kinase M2 
(PKM2) expression on breast cancer cell lines - MDA-MB-231 and MCF-7 cells.   
Understanding the molecular pathways that link tumor biology to the staggering 
array of pathologies and genes is of paramount scientific and medical importance. 
Our results have established previously unknown novel cross-link between HHQ, 
PPARγ, apoptosis and glycolysis; thereby adding a new dimension to therapeutic 
potential of PPARγ ligands. These investigations will help us in understanding the 
molecular mechanisms by which PPARγ regulates the cellular energy pathway and 
opens a new direction for development of its ligand - HHQ in human breast cancer 
therapeutics. 
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CHAPTER 1 
 
 INTRODUCTION 
 
1.1   BACKGROUND 
     Breast cancer is the second most common cancer globally and accounts for the 
highest morbidity and mortality. It is the second highest occurring cancer in women and 
one of the leading causes of death. Despite advances in early detection, effective 
endocrine therapy and understanding of the molecular bases of breast cancer 
pathophysiology, a significant proportion of patients have acquired resistance to the 
drugs, increased side effects of the therapies and about 30% of patients with early-stage 
breast cancer have recurrent disease.  Hence, there is a requirement for alternative 
therapeutics with increased efficacy and low toxicity, based on the patient and the 
clinical and molecular characteristics of the tumor.  
    Currently, researchers are focusing on the target-based therapy involving modulation 
of transcription factors by ligands, which play critical roles in tumorigenesis such as 
tumor development and progression as well as metastasis. Transcription factors can be 
used as potential molecular therapeutic tools in cancer development and progression to 
regulate transcriptional levels of genes associated with disease, verify gene function and 
to validate target genes for drug design.  
 
1.2   BREAST CANCER BURDEN 
      Breast cancer is the second most common cancer in the world and the most frequent 
cancer among women with an estimated 1.67 million new cancer cases diagnosed in 
2012 representing about 12% of all new cancer cases and 25% of all cancers in women. 
It is the most common cancer in women both in the developed and less developed 
regions with more cases in less developed (883,000 cases) than in more developed 
(794,000) regions [1]. 
 
1.3 BREAST CANCER RISKS 
      Although several risk factors for breast cancer have been well documented but for 
the majority of women suffering with breast cancer it may not possible to identify 
specific risk factors. Lifestyle, genes and environment together contribute to the 
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probability of developing female breast cancer. Known risk factors for breast cancer 
includes, obesity, BRCA mutations, change in endogenous hormone levels, exogenous 
hormones etc. [2]. Lacey et al. [3], evaluated known risk factors for breast cancer 
among 70,575 women in a cancer screening trial. They calculated relative risks for 
lifestyle and reproductive factors for 5 years from date of randomization. They found 
that increasing age, positive family history of breast cancer, nulliparity, and use of 
menopausal hormone therapy were positively associated with breast cancer. 
Unexpectedly menarche and menopause were less strongly associated with breast 
cancer. Only severe was statistically significantly associated with breast cancer. 
 
1.4   AVAILABLE THERAPIES FOR BREAST CANCER  
     Different types of treatment are available for patients with breast cancer. Treatment 
for breast cancer depends on the kind, severity and invasiveness of the breast cancer. 
People with breast cancer often get more than one kind of standard treatment depending 
upon the severity of the breast cancer. Available therapies for breast cancer are 
described below. 
1.4.1  Surgery: 
      Many patients with breast cancer have surgery to remove the cancer from the breast. 
Surgeries include, lumpectomy (remove tumor or lump), partial mastectomy, (remove 
the tumor and breast tissues surrounding the tumor), total mastectomy (remove the 
whole breast that has cancer) and modified radical mastectomy (remove the whole 
breast that has cancer, lymph nodes and chest muscles). The patient may be given 
chemotherapy to remove the tumor or shrink the tumor size. Chemotherapy before the 
surgery is done to reduce the amount of tissues removed dire to surgeries. This kind of 
treatment is called neo adjuvant therapies. Some times after the surgeries patients may 
be given radiation therapy, hormone therapy or chemotherapy to kill the breast cancer 
cells left after surgery in order to lower the chances of reoccurrence.   This kind of 
treatment is called adjuvant therapy.  
1.4.2    Radiation therapy 
        Radiation therapy involves cancer treatment with high-energy x-rays or other 
types of radiation to kill cancer cells. There are two types of radiation therapies.  In 
external radiation therapy the body is exposed to the radiation externally by a machine 
to treat the breast caner where as in case of internal radiation therapy involves direct 
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contact of radioactive substance into or near the cancer by needles or catheters. It 
depends on the stage and the type of cancer to be treated by radiation therapies. 
1.4.3    Hormone therapy 
       Estrogens are female hormones that are primarily secreted by ovaries. Once the 
estrogen binds to the receptors, which can cause estrogen positive breast cancers to 
grow. Anti-estrogen therapy or hormone therapy involves manipulation of the endocrine 
system by blocking receptor binding with an antagonist or by depriving the tumor of 
estrogen. The Estrogen is the major driver in the majority of breast cancers and is 
expressed in 75% of breast cancers overall. Currently, aromatase inhibitors are used to 
block the enzyme aromatase, which synthesizes estrogen in the body. Some popular 
aromatase inhibitors are Arimidex (anastrozole), aromasin (exemestane) and femara 
(letrozole). Treatment to stop the ovaries from making estrogens is called ovarian 
ablation.  
1.4.4   Chemotherapy 
       Chemotherapy uses drugs to stop the cancer cells from growing or dividing. The 
drugs when taken orally and intravenously enter the bloodstream and are able to reach 
the cancer cells throughout the body, this type of therapy is called systemic therapy. But 
when drugs are placed directly into the affected area such as organ or cerebrospinal, this 
is called regional chemotherapy. The type of chemoptheaputic treatment given to patient 
depends on the type and stage of the cancer being treated. There are many drugs for 
breast cancer approved by Food and Drug Administration (FDA).  The individual drugs 
are approved by FDA, however now a days many combination of drugs are used by 
breast cancer patients which are not approved by FDA. The drugs for treatment of 
breast cancer are described below [4]. 
 
1.5    BREAST CANCER RESISTANCE  
        The effectiveness of breast cancer treatment is limited due to high de novo 
resistance and resistance acquired during treatment by the breast cancer cells. The 
potential mechanisms involved in intrinsic or acquired endocrine resistance are still 
poorly comprehended [5]. The important diagnostic and therapeutic challenges in 
current breast cancer research are therefore to identify the factors and pathway 
responsible for the resistance, and the ways to overcome it.  
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      Tamoxifen, a nonsteroidal (selective estrogen receptor modulator) SERM, is FDA 
approved drug for the treatment of breast cancer [6]. It inhibits breast cancer growth 
through competitive blocking of the estrogens (ER), thereby inhibiting estrogen-induced 
growth. Tamoxifen has shown to inhibit more than half of patients with metastatic ER-
positive tumors disease. Although the tamoxifen is initially effective in many patients, 
but due course the tumors develop resistance [7]. Despite the presence of ER almost 
50% of breast cancers, fail to respond to tamoxifen. This acquired resistance to 
tamoxifen by breast caner is attributed by either de novo at the beginning of the 
treatment or acquired after prolonged treatment, to be stimulated rather than inhibited 
by the drug [8,9]. Osborne et al [10] studied an in vivo ER-positive MCF-7 human 
breast cancer cells xenograft model of tamoxifen-stimulated tamoxifen resistance, in 
nude mice. They observed that Tamoxifen treatment initially suppresses tumor growth 
for several months, but later tumor grew as the tumors become stimulated by the drug.  
      Evidences suggest that ER and GF (Growth factor) - receptor pathways 
(EGFR/HER2 family and IGF-I receptor) contributes to endocrine resistance [6]. 
Studies by Nickolsan [11], confirmed that the increased GF signaling pathways may 
account for loss of some estrogen dependence, resulting in anti estrogen-resistant 
tumors. They found out that the acquired resistance of MCF-7 cells in vitro is 
associated with increased levels of EGFR and MAPK activity after long-term treatment 
with tamoxifen. The key signaling kinases, including p42/44MAPK, the stress-related 
c-Jun NH2-terminal kinase and p38 MAPKs, and protein kinase A, AKT, have all been 
reported to activate the ER pathway by direct phosphorylation of the ER, its 
coactivators, or both [12-14]. Schith et al [15,16] has shown in the preclinical studies, 
de novo and/or acquired tamoxifen resistance is associated with increased levels of 
these different kinases. Benz at al [17] demonstrated in human breast cancers 
overexpressing HER2 xenograft model are resistant to tamoxifen. Some studies too 
correlated High HER2 expression with tamoxifen resistance in patients in some studies 
[18].  Also high levels of activated ER coactivator AIB, reduce the antagonist effects of 
tamoxifen in tumors that also overexpress GF receptors, such as HER2. AIB1 is 
phosphorylated and activated by kinases p42/44 MAPK, which in turn can be activated 
by HER2 [19]. According to Osborne et al. [5] tumors with high abundance of 
coactivators, such as AIB1, and enhanced HER2 signaling, which can activate AIB1, 
are less responsive to tamoxifen therapy due to increased estrogen agonistic activity of 
tamoxifen. 
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1.6 NEED OF ALTERNATIVE THERAPIES FOR BREAST CANCER  
     Extreme side effects of chemotherapy, radiation, reoccurrence of breast cancer after 
therapy, increased metastasis and increased resistance acquired de novo or during the 
course of treatment to drugs had led the focus to shift on new-targeted therapies. New 
targeted therapies such as target specific drugs may be a promising approach to 
improve present treatment strategies and overcome endocrine resistance.  
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1.10 COMPOSITION OF THESIS 
This thesis involves mainly two objectives based on target therapy for breast cancer:  
1. To identify computationally novel transcriptional factors of nuclear hormone 
receptor - peroxisome proliferator activated receptor gamma (PPARγ) involved 
in breast cancer pathophysiology and validate the identified PPARγ novel targets 
by its natural ligand 15-Deoxy-Δ12, 14-prostaglandin J (15d-PGJ2). 
2. Identification and functional validation of novel PPARγ ligands on the above 
identified novel transcriptional targets of PPARγ. 
Chapter 1 gives a brief introduction of breast cancer burden in the world, available 
therapies for breast cancer and reasons for need of alternatives for breast cancer therapy. 
In addition, the details of resistance acquired by breast cancer is also discussed in detail. 
Furthermore, PPAR gamma mechanism of action, its role in cancer and its 
transcriptional targets are also discussed in detail.  
Chapter 2 focuses on computational identification of PPARγ binding motifs, PPRE and 
PACMs in the whole human genome by PPRE search tool and in vitro validation of the    
putative PPARγ targets in human breast adenocarcinoma, MDA-MB-231 and MCF-7.   
Chapter 3 focuses on the in vitro validation of proposed PPARγ ligand - coffee 
component, Hydroxyl Hydro Quinone on identified novel transcriptional targets of 
PPARγ in human breast adenocarcinoma, MDA-MB-231 and MCF-7. In addition effect 
of HHQ on the cytotoxicity and mechanism of death in MDA-MB-231 and MCF-7 is 
also investigated. 
Chapter 5, conclusion is drawn based upon my research and summarized it. I addition 
the potential and future direction of my research is discussed briefly.  
 
 
 
 
 
 
 
 
 
 
 
 
	   20	  
CHAPTER 2 
 
COMPUTATIONAL IDENTIFICATION AND VALIDATION OF 
NOVEL TRANSCRIPTIONAL TARGETS OF PPAR GAMMA IN 
BREAST CANCER PATHOPHYSIOLOGY 
 
2.1 INTRODUCTION 
       Peroxisome proliferator-activated receptors (PPARs) belong to the nuclear hormone 
receptor superfamily of ligand-activated transcription factors. Upon ligand activation, 
PPAR translocates from cytoplasm to nucleus and heterodimerizes with retinoid X 
receptor (RXR) to regulate gene expression. Three isoforms (α, β, and γ) for PPAR have 
been identified so far in Xenopus, mouse, human, rats, and hamsters. The PPAR subtypes 
share a highly conserved DNA-binding domain that matches with specific DNA 
sequences known as peroxisome proliferator response elements (PPREs). These PPAR 
isoforms are encoded by different genes, perform different functions and exhibit different 
tissue localizations [75-80]. Imbalances in expression of target genes that have a pivotal 
role in regulating metabolic syndrome and cancer through atherogenic metabolic 
triad/lipid triad metabolism has recently been noted to be modulated by PPARs [81]. 15-
Deoxy-Δ12, 14-prostaglandin J (15d-PGJ2) is a natural ligands [82]. It is prudent to note 
that the expression of PPARγ in tumor breast tissue is significantly higher than in normal 
breast epithelium.  
      Toward this end, development of a new class of anticancer drugs through a new 
approach employing PPARγ activators to inhibit proliferation and increased cell death in 
breast cancer cell lines is hypothesized. Concurrently, PPARγ is also reported to control 
the expression of genes involved in differentiation and is also reported to negatively 
regulate the cell cycle [83, 84]. PPARs are also involved in various independent and 
DNA-dependent molecular and enzymatic pathways in adipose tissue, liver and skeletal 
muscles. PPARγ activation is reported to inhibit the proliferation of malignant cells, 
including those derived from liposarcoma, breast adenocarcinoma, prostate carcinoma, 
colorectal carcinoma, non small-cell lung carcinoma, pancreatic carcinoma, bladder 
cancer, gastric carcinoma, and glial tumors of the brain [85-88]. Thus, PPARs can 
provide therapeutic targets for several diseases such as dyslipidemia, diabetes, obesity, 
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inflammation, neurodegenerative disorder, and cancer. Recently, it was showed that 
activation of PPARγ inhibits the expression of Na+/H+ exchanger 1 (NHE1) that was 
associated with the sensitization of breast cancer cells to chemotherapeutic treatment 
[89]. Hence, modulation of PPARγ receptor action in these diseases may be of 
therapeutic value. The effect of PPARγ ligands on breast cancer cell motility and the 
plasminogen activator system has also been investigated [90]. The metabolic phenotype 
of cancer is distinct from that of normal cells. In comparison to the normal aerobic 
glucose metabolism pathway, which uses mitochondrial oxidation, cancer cells develop 
Warburg’s effect, in which aerobic glycolysis is increased and for which drug-driven 
disruption might lead to minimal side effects [91]. Altenberg and Greulich [92], found 
overexpression of glycolytic genes in 24 cancer cell lines Hypoxic tumors have generally 
been known to evolve into invasive and metastatic tumors as compared to those with 
normal oxygen levels due to increase glycolysis requirements in hypoxia. These results 
demonstrated the clinical importance of glucose metabolism in treatment of cancer. 
Hence, disruption of Warburg effect may help resolve the malignant process 
independently of tumor origin and is likely to have broad therapeutic implications. 
      It is of interest to mention that DNA-binding activity of PPARγ is modulated by the 
isotype of the RXR heterodimeric partner. Chandra et al [93] reported structures of intact 
PPARγ and RXRα as a heterodimer bound to DNA, ligands and coactivator peptides. It 
was observed that PPARγ and RXRα form a non-symmetric complex, allowing the 
ligand-binding domain of PPARγ to contact multiple domains in both proteins. PPREs 
are described to consist of juxtaposed degenerate hexamer AGGTCA separated by one 
nucleotide, direct repeat 1 (DR1) or two nucleotides (DR2), suggesting that both DR1 and 
DR2 sites could be bound by PPARγ-RXRα nuclear receptor complex [89, 94]. Apart 
from the effects of PPARγ on cell death, none of the studies on the effect of PPARγ on 
breast cancer demonstrates the molecular mechanisms, pathways, or genes that are 
modulated by PPARγ to cause cell death.  
      Breast cancer is the fifth most common cancer globally and accounts for the highest 
morbidity and mortality. It is the second highest occurring cancer in women and one of 
the leading causes of death [95]. Although anti-estrogens have provided an effective 
endocrine therapy, a significant proportion of patients have acquired resistance to these 
drugs. Hence, there is a requirement for alternative therapeutics to treat breast cancer. It is 
pertinent to screen drugs with a potential to target critical molecules involved in 
metabolic transformation because several drugs that inhibit metabolism of cancer cells by 
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targeting a variety of molecules (including enzymes) directly or indirectly, are currently 
under clinical trials [96].  
 The main objective in this chapter is to identify novel PPARγ target genes which 
are reported to be involved in breast cancer, followed by their functional classification, 
disease ontology (DO) and network construction. Further investigations on these could 
possibly help us in understanding the molecular mechanisms by which PPARγ regulates 
disease targets specifically in breast cancer and the use of its ligands in breast cancer 
therapeutics. 
 
2.2    EXPERIMENTAL SECTION 
2.2.1  COMPUTATIONAL METHODOLOGY 
  Computational identification of PPRE in genome data 
      The sequences 5 kb upstream of annotated transcription starts of human RefSeq 
genes were downloaded from UCSC genome browser (http://genome.ucsc.edu/) [97]. 
The sequences downloaded were from the February 2009 assembly of the human 
genome (hg19, GRCh37 Genome Reference Consortium Human Reference 
37(GCA_000001405.1). The PPRE motifs were searched in the 5 kb promoter region of 
the genes using the PPRESearch tool in command line mode (http://the- 
systembiology.com/OVista/PPRE2/) [89]. PPRESearch is a database searching tool that 
contains a comprehensive collection of experimentally validated PPRE motifs reported 
in literature and allows the user to search for PPRE motifs in a gene of interest. Gene 
promoters whose PPREs match exactly with experimental PPREs were selected. Both 
DR1 and DR2 PPREs were searched. Recently, a 15 bp novel motif PACM (PPAR-
associated conserved motif) was reported [98]. I also included this motif in our search. 
Since the gene sequences were represented by transcript ID, their corresponding gene 
symbols and gene names were retrieved using the gene ID conversion tool from 
DAVID http://david.abcc.ncifcrf.gov/ [99]. Genes that have more than one transcript ID 
(due to gene polymorphism) have same gene symbol and same PPRE sites and hence 
were grouped together under one gene name. 
Collection of genes for breast cancer 
      The genes involved in breast cancer pathophysiology were collected from several 
sources such as literature, Gene cards database (http://www.genecards.org) [100] and 
the Breast Cancer Gene Database (BCGD) (http://mbcr.bcm.tmc.edu/ermb/bcgd/bcgd. 
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html) [101]. A total of 2332 non-duplicate genes were to be involved directly and 
indirectly in breast cancer pathophysiology. 
Identification of genes that have PPRE and are reported to be involved in breast 
cancer 
       A total of 217 breast cancer genes were found to be having the PPRE motif and/or 
the PACM motif. 
 PPARγ target identification 
Protein–protein interaction and molecular interaction network   construction  
      The complex global network of protein interactions dictates cellular behavior. The 
putative PPARγ targeted breast cancer genes were mapped to the Biological General 
Repository for Interaction Datasets (BioGRID) version 3.1.91 a curated protein–
protein and genetic interactions database to identify the interacting partners 
(http://www.thebiogrid.org). BioGRID is a public data- base with 48,831 human 
protein interactions compiled through comprehensive curation efforts (10,247 
publications) [102]. 
Gene Ontology, protein and pathway 
      The PANTHER (Protein ANalysis THrough Evolutionary Relationships) 
classification System is a unique resource that classifies genes by their functions, using 
published scientific experimental evidence and evolutionary relationships to predict 
function even in the absence of direct experimental evidence 
(http://www.pantherdb.org/). The genes were classified according to GO classes: 
molecular function, biological process, cellular component, PANTHER protein classes 
and pathways [103]. 
Functional Disease Ontology 
     In order to find the enrichment of predicted PPARγ breast cancer target gene set in 
various disease profiles I mapped the gene set to Functional DO (FunDO) tool. DOLite 
has been used in the FunDO Web application. FunDO is an online tool from 
Northwestern University Feinberg School of Medicine’s own Biomedical Informatics 
Core (NUBIC), to find out disease association with gene of interest 
(http://projects.bioinformatics. northwestern.edu/fundo/) [104]. 
Network construction 
      Disease gene network and protein interaction network were drawn using Cytoscape. 
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Cytoscape is an open source bioinformatics software platform for visualizing molecular 
interaction networks and also integrates these interactions with gene expression profiles 
and other state data [105]. It is available at http://www.cytoscape.org/. Though scale 
free networks do not have a well-defined threshold for a node to be a hub, several 
researchers have defined a degree threshold. Gaci [106] recently proposed that any node 
with a degree higher that 3/2 times of z (average degree), could be considered as a hub. 
I have used the above procedure for identification of hubs in our network. Network 
parameters such as the node degree, betweenness centrality and stress centrality were 
calculated using Cytoscape plug-in CentiScaPe [107]. Degree is an estimate on the 
regulatory relevance of the node. In biological networks, proteins with very high degree 
interact with several proteins, thus suggesting a central regulatory role that is they are 
likely to be hubs. The centrality value of a node can be interpreted as the probability of 
a protein to be functionally capable of organizing discrete protein clusters or modules. 
Thus, a protein with high centroid value, compared to the average centroid value of the 
network, will be possibly involved in coordinating the activity of other highly connected 
proteins. Stress of a node indicates the relevance of a protein as functionally capable of 
holding together communicating nodes. Thus, stress simply indicates a molecule heavily 
involved in cellular processes. Betweenness of a node in a network indicates the 
relevance of a protein as functionally capable of holding together communicating 
proteins. Proteins with high betweenness value are crucial in maintaining functionality 
and coherence in biological mechanisms [107]. All the centralities are calculated 
simultaneously in this special plug in. 
Target selection 
      I further focused on energy generation pathways and selected two glycolytic genes 
phosphoglycerate kinase 1 (PGK1) and pyruvate kinase M2 (PKM2) for experimental 
validation on their regulation by PPARγ. These genes were selected because they were 
reported to be involved in breast cancer in literature [92], they had PPRE motif but were 
not earlier reported to be regulated by PPARγ. Also, they were at important steps in 
biological pathway and were hubs. Here, it must be mentioned that PGK1 has a node 
degree of 13 and PKM2 has a node degree of 10. 
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2.2.2  EXPERIMENTAL VALIDATION METHODOLOGY 
Reagents 
      Dulbecco’s modified Eagle’s medium (1000 mg/L glucose, l-glutamine, and sodium 
bicarbonate), Fetal bovine serum, 15-deoxy-Δ12, 14-Prostaglandin J and crystal violet 
were purchased from Sigma-Aldrich, St Louis, MO, USA. Penicillin–Streptomycin–
Neomycin antibiotic mixture and Hoechst 33,258 were procured from Hoechest; 
Invitrogen, Eugene, OR, USA and JC-1 dye from Biotium (Hayword, CA, USA). 
Sodium chloride, potassium chloride, Tris base, glycine, sodium phosphate di basic, 
sodium di hydrogen phosphate were purchased from Wako Pure Chemical Industries, 
Osaka, Japan. 
Cell culture and treatment 
      The human breast adenocarcinoma cell lines MDA-MB-231 and MCF-7 were 
purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA). 
The carcinoma cells were maintained in Dulbecco’s modified eagle’s medium 
supplemented with 10% fetal bovine serum and PNS antibiotic mixture 100 ng/mL at 
37°C and 5% CO2/95% O2. Cells at about 50% confluency were treated with 5 and 10 
µM of 15-deoxy-Δ12, 14-Prostaglandin J for 48 h and harvested for further use. 
Cell viability analysis 
      Cell viability was assessed using MTT cell proliferation assay kit (Roche, 
Mannheim, Germany) following manufacturer’s instructions. This assay is a 
nonradioactive cell proliferation assay that identifies living cells, and is based on the 
cellular conversion of a tetrazolium salt into a formazan product, a chromophore, which 
can be quantified by spectrophotometry. 104 cells/well were plated in 96-well plates. 
Cells were grown for 24 h followed by 48 h treatment of 5 and 10 µM of 15-deoxy-Δ12, 
14-Prostaglandin J2. The intensity of the reduced dye which corresponds to the viable 
cells was measured at 570 nm wavelength by Thermo Scientific Varioskan Flash 
Multimode Reader. 
Western blot analysis 
      The cells were lysed in RIPA lysis buffer (25 mM Tris–HCl (pH 7.6), 150 mM 
NaCl, 1% NP-40, 1% sodium deoxy cholate, 0.1% SDS) complemented with complete 
protease inhibitors (Roche) for 15 min on ice followed by centrifugation at 14,000 g for 
15 min at 4°C. The protein concentration was determined using BCA reagents (Pierce, 
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Rockford, IL, USA). Twenty microgram of protein was resolved in 10% in SDS-
polyacrylamide gel under standard denaturing conditions according to Laemmli’s 
method (1970). The proteins were transferred onto polyvinylidene difluoride 
membranes using a Trans-Blot SD (Bio-Rad, Lewes, E. Sussex, UK.) semi-dry 
electroblotter for 30 min at 20 V. Subsequently, the membranes were blocked for 45 
min at room temperature (RT) with 2% bovine serum albumin in 0.1% PBST. The 
membranes were then probed with anti-PGK1 (1:1000; Abcam, Cambridge, UK), anti- 
PKM2 (1:500, Abcam), anti-PPARγ (1:000; Cell Signaling), anti-caspase 8 (1:1000; 
Cell Signaling, Boston, MA, USA), anti-β-actin (1:20,000; Abcam) at 4°C overnight 
followed by three washes for 5 min each with 0.1% PBST. The membranes were then 
incubated with horseradish peroxidase conjugated secondary antibody (1:20,000; 
Abcam) for 45 min at RT and washed thrice for  5 min each with 0.1% PBST 
followed by chemiluminescent detection using luminescent image analyser equipped 
with charge-coupled device camera (LAS-4000 Ver. 2.1; Fuji Film, Tokyo, Japan). 
 ATP depletion studies 
       In order to examine the extent of ATP depletion due to PPARγ activation, I next 
examined ATP concentration in cytosol and mitochondria. ATP concentration was 
quantified using commercially available luciferin – luciferase bioluminescence assay kit 
(Molecular Probes, Inc., Eugene, OR, USA). The assay is based on luciferase’s 
requirement for ATP in producing light (emission maximum ~560 nm at pH 7.8). 
Mitochondria from cultured cells were isolated using a mitochondria isolation kit 
according to manufacturer’s instructions (Pierce Biotechnology, Inc., Rockford, IL, 
USA). ATP level was estimated in cytosolic and mitochondrial fraction according to 
manufacturer’s instructions. The amount of ATP in the experimental samples was 
calculated from standard curve prepared with ATP (1–100 µM) and expressed as 
percentage of ATP in cells. Light emission was monitored using a luminometer (Wallac 
1420 Victor 2 multiplate counter system; Perkin Elmer Life Science, Inc., Gaitherburg, 
MD, USA). 
Hoechst staining 
      To determine the nuclear condensation and DNA fragmentation in cells undergoing 
apoptosis I stained the nucleus with nucleus specific stain Hoechst 33258, pentahydrate 
(bis-Benzimide) (Molecular Probes, Inc.). The cells were cultured on glass coverslips 
and treated according with 15d-PGJ2 concentrations. Cells were fixed with ice-cold 
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methanol: acetone (1:1) for 10 min at –20°C and later permeabilized with 0.32% PBST 
(PBS-Triton). Subsequently, coverslips were washed and exposed to Hoechst 33258 
(0.5 µg/ml) in the dark at room temperature for 15 min. After washes, the ProLong+® 
Gold anti- fade reagent (Molecular Probes, Inc.) was dropped onto the coverslips and 
the fluorescent images were captured using Zeiss LSM 700 Zen 2009 confocal 
microscope. 
Assessment of mitochondrial membrane potential (∆ψ) 
      Mitochondrial transmembrane potential was investigated using a fluorochrome, JC-
1 dye (Biotium). JC-1 has the unique property among ΔΨm-sensitive fluorophores of 
developing large shifts in its fluorescence signal at the levels of uptake induced by the 
high ΔΨm characteristic of energized mitochondria. This is due to the formation of red 
fluorescent (595 nm) J-aggregates of the molecule in the mitochondrial matrix. At the 
levels of JC-1 uptake seen during low ΔΨm, the fluorophore remains as a green 
fluorescent (535 nm) monomer [108,109]. The reciprocal behavior at the two emission 
wavelengths, which can easily be measured simultaneously, results in large changes in 
the 595/535 nm ratio [110]. Only the multimeric, red fluorescent form of JC-1 
specifically measures ΔΨm-dependent mitochondrial uptake of the probe. The green 
fluorescence of the monomeric form may be highly sensitive to its distribution in non-
mitochondrial cell membranes. This dye accumulates in intact mitochondria and forms 
aggregates under influence of difference in potential where as it remains monomer in 
cytosol with characteristic absorption and emission spectra. After 48 h of 15d-PGJ2 
treatment, the cells were incubated with 1X JC-1 dye at 37°C for 15 min followed by 
washes with assay buffer. The JC-1 labeled cells were analyzed by fluorescence 
microscope (Zeiss LSM 700 Zen 2009) confocal microscope and photographed. JC-1 
appeared to be particularly useful for following changes in ΔΨm during the model.  
Statistical Analysis 
       All experiments were performed in triplicates. The quantitative data is presented as 
mean ± SEM. Statistical analysis was performed using analysis of variance (One way 
ANOVA) followed by Bonferroni’s on test to determine differences in mean and p < 
0.05 was considered as statistically significant. 
 
2.3 RESULTS AND DISCUSSIONS 
       I identified 217 genes from human genome reported to be involved directly or 
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indirectly in breast cancer that contain the PPRE and/or PACM motifs and could 
possibly be regulated by PPARγ. Interestingly, majority of PPARγ target genes are 
involved in biological processes such as cell cycle, cell–cell signaling, and signal 
transduction. Other important molecular functions that PPARγ target genes are 
associated with include transcription factor activity, protein kinase activity, and 
transmembrane protein kinase activity. The functional DO shows their involvement in 
cancer, breast cancer, and diabetes mellitus among several other disorders. These data 
suggest the important role of these genes in the listed disorders and could possibly 
contribute toward understanding their molecular mechanism. 
2.3.1 Computational identification of PPARγ-binding sites in genes involved in 
breast cancer pathophysiology  
      The steps involved in identification of potential targets of PPARγ involved in breast 
cancer and their associations with diseases are outlined in Figure 2-1. A total of 217 
breast cancer genes were predicted as putative PPARγ targets (Table 2-1).  
 PPARγ target identification 
Protein–protein interaction and molecular interaction network construction 
      I further undertook protein–protein interaction analysis to find the interacting 
partner of these 217 genes using BioGRID database. Further, to identify important hubs 
(targets) I constructed an interacting network (Figure 2-2) and calculated centrality 
parameters; node degree, closeness, betweenness, and stress using CentiScape plug-in. 
All nodes above the degree value of 5.55 were considered as hub for this analysis [106]. 
The highest value for node degree, betweenness, and stress was 238, 844494.11, and 
5520696, respectively. The lowest calculated values for degree, betweenness, and stress 
was 1.0, 0, and 0, respectively. The average value of the node degree, betweenness and 
stress was 3.7, 6242.74, and 46561.29, respectively. BRCA1 scores the highest for all 
the three centrality parameters (Table 2-2). The node degree, betweenness, and stress 
for PGK1 was 13, 29554.82, and 191676, respectively whereas for PKM2 the node 
degree, betweenness, and stress was 10, 19079.22, and 110048, respectively. 
Gene Ontology, protein class and pathways 
      I analyzed the GO terms for all the 217 PPARγ target genes that are associated with 
breast cancer pathophysiology (Figure 2-3). The analysis revealed that cell cycle (52), 
cell–cell signaling (30), and signal transduction (28) were the most common GO 
categories representing biological processes. A total of 855 classifications were 
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identified suggesting that several proteins are involved in more than one biological 
process. A total of 280 classifications were identified under the molecular function and 
the three most abundant were transcription factor activity, protein kinase activity, and 
transmembrane protein kinase activity. The non-receptor serine threonine protein kinase 
class of proteins was amongst the most represented, comprising 30 protein entries 
followed by nucleic acid binding proteins with 19 entries. 
Functional Disease Ontology 
     Functional gene ontology is a tool to study the gene disease relationship. These 
studies greatly facilitate understanding of pathogenesis, which could lead to better 
diagnostics and treatments. DOLite is a simplified vocabulary list from the Disease 
Ontology (DO). It has been used in the FunDO (FunDO) Web application [104]. Here, I 
undertook functional enrichment test for 217 PPARγ target genes. All the genes were 
found to be associated with diseases. My disease gene network shows predominant role 
of PPARγ in cancer in general (18.5%), followed by breast cancer (10.1%), and prostate 
cancer (8.9%) (Figure 2-4). Notably, diabetes mellitus, atherosclerosis and rheumatoid 
arthritis are other important disorders, with 15, 12, and 13 PPARγ target genes, 
respectively. All nodes above the degree value of 6.68 were considered as a hub for this 
analysis [106]. The highest value for node degree, betweenness, and stress was 33, 
4620.93, and 68152, respectively whereas the lowest calculated values for degree, 
betweenness, and stress was 1.0, 0, and 0, respectively. The average value of the node 
degree, betweenness, and stress was 4.55, 272.47, and 4616.38. Cancer had the highest 
centrality parameters in protein–protein interaction network (Table 2-3) whereas the 
gene associated with maximum number of diseases was SERPINE1 with centrality 
parameters as node degree (15), betweenness, (1818.93) and stress (33750) (Table 2-4). 
SERPINE1 is a serine protease inhibitor (serpin) protein and is recently reported to be 
over expressed in colorectal cancer associated with tumor invasiveness and 
aggressiveness [111]. It has been reported to be modulated by PPARγ [112]. 
Target selection for experimental validation on their regulation by PPARγ  
           Panasyuk et al. [113] recently reported that the PPARγ transcription factor and 
nuclear hormone receptor contributes to selective PKM2 and hexokinase 2 gene 
expression in PTEN-null fatty liver. However, there are no reports on the regulation of 
PGK1 and PKM2 by PPARγ in breast cancer and our understanding of molecular 
mechanisms selectively controlling specific glycolytic enzymes is limited. It was 
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interesting to note that several glycolytic genes had PPRE motif. Here, I report for the 
first time the down regulation of two key glycolytic genes—PGK1 and PKM2 by 
PPARγ upon ligand activation. PGK1 and PKM2 catalyze the sixth and ninth step, 
respectively, in the glycolysis pathway generating two ATPs each. Additionally M2 
isoform of pyruvate kinase has been reported as the key regulator in maintaining 
metabolic budget system in tumor cells [114].  
       Glycolysis is the initial stage of glucose metabolism, the conversion of glucose into 
pyruvate and generation of energy in the form of ATP. Coordinated upregulation of 
glycolysis pathway proteins has been reported in several different tumor types [119-
117] including breast cancer [118]. Recently, it was also suggested that women with 
breast cancer have increased levels of glycolytic proteins in plasmas [119]. Mechanisms 
such as gene amplification, increased gene expression, increased translation, 
posttranslational modification, and regulation by protein–protein interactions in the 
cytoplasm or even small RNA networks or RNA interference make possible 
enhancement of glycolysis [92]. Given this large number of different mechanisms, and 
the assumption that carcinogenesis is the result of a large number of stochastic events, 
one might expect that different cancers exploit different mechanisms to achieve 
increased glucose consumption owing to the variety of mechanisms and acceptance of 
the postulate that the underlay of carcinogenesis is a large number of stochastic events. 
The complexity of the underlying biochemical and molecular mechanisms of breast 
cancer make metabolic reprogramming in breast cancer unclear.  
       In this study, I carried out prediction of PPRE motifs in glycolytic genes to 
determine the possible role of PPARγ in altered regulation of glycolysis in tumor 
metabolism and explored PPARγ as the potential link between energy balance, cellular 
metabolism, and cancer pathogenesis. 
2.3.2   Cytotoxic and anti-proliferative effect of micromolar concentration of 15d-
PGJ2 for PPARγ activation in breast cancer cells   
      Breast cancer cells were exposed to 15d-PGJ2 concentrations of 3, 5, 10, 15, and 20 
µM for 48 h. The cytotoxic and anti-proliferative effect of 15d-PGJ2 was assessed by 
MTT dye reduction assay. The IC-50 value for MDA-MB-231 and MCF-7 were found 
to be 10 and 15.9 µM, respectively. I preferred to proceed with 10 µM to see the 
comparable effects of same concentration on both the cell lines. As shown in Figure 2-5, 
cell numbers decreases in dose-dependent fashion. 
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2.3.3  Constitutive expression levels of PPARγ in breast cancer cells 
       To assess whether inhibition of cells’ growth by PPARγ ligand, 15d-PGJ2 is a 
function of PPARγ expression, I first screened two representative breast cancer cell 
lines, MDA-MB231 and MCF-7 for expression of PPARγ protein. I observed MDA-
MB-231 cells expressed higher level of PPARγ protein than MCF-7. MDA-MB-231 
was found to have 2.4-folds higher level of PPARγ as compared to MCF-7, which 
accounted for its higher susceptibility toward PPARγ activation by 15d-PGJ2 (Figure 2-
6). The results are comparable with studies of Huang et al. [120].  
2.3.4 Repression of glycolytic enzymes upon activation of PPARγ by its natural 
ligand  
      PGK1 and PKM2 are reported to be over expressed in many cancers [92] accounting 
for their pivotal role in most fundamental metabolic alterations [91]. Down regulating 
these enzymes would not only starve the cells for ATP but also for building blocks like 
amino acid and nucleic acid precursors. Here, I hypothesized that PGK1 and PKM2 
expressing PPRE motifs may be modulated upon activation of PPARγ. Therefore, I 
undertook expression analysis of these metabolic enzymes in order to examine the 
above hypothesis. I observed reduction in expression of PGK1 (Figure 2-7) and PKM2 
(Figure 2-8) with increase in 15d-PGJ2 concentration. These results were comparable 
with results from anti-proliferative studies. Similar results for PGK1 were observed in 
prostate cancer cells by Venkatachalam et al. [89]. 
2.3.5  Decrease in energy currency level upon repression of glycolytic genes  
       ATP plays an important role in metabolism, irrespective of whether it is being 
produced or used. Since both the enzymes are involved in ATP synthesis I hypothesized 
that with repression in PGK1 and PKM2, the ATP level will be altered. Therefore, to 
test this hypothesis I undertook ATP depletion studies in cytosol and mitochondria in 
both the breast cancer cell lines. Significant depletion of the cytosolic ATP and 
mitochondrial ATP level was observed. However I observed higher level of ATP 
depletion in MDA-MB-231 as compared to that in MCF-7, which could possibly be 
related to higher basal expression of PPARγ in MDA-MB-231 (Figure 2-9).  
2.3.6  PPARγ activation leads to apoptosis in breast cancer cells 
      Patel et al. [121] observed that the activation of PPAR by its selective ligand, 
rosiglitazone, upregulates PTEN expression in human macrophages, Caco2 colorectal 
cancer cells, and MCF-7 breast cancer cells possibly by binding to two putative PPREs 
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identified within the PTEN promoter. As a result of upregulated PTEN, Akt 
phosphorylation and concomitant cell proliferation was significantly reduced. It was 
also shown that PPARγ-dependent PTEN expression could be blocked by estrogen 
receptor binding to the PPRE site of the PTEN promoter [122]. This crosslink has to be 
carefully considered when new therapy approaches are developed.  
      Downregulation of PGK1 and PKM2 decreases ATP production in the cytoplasm 
and mitochondria, initiating apoptosis and suppressing cancer metabolism. ATP 
depletion, used in combination with chemotherapy and/or radiation, has a variety of 
effects on cancer cells including inducing apoptosis in multidrug resistant cells and 
decreasing tumor promotion. Cellular ATP level has been reported as an important 
determinant of cell death [123]. The exact mechanisms of these effects have not been 
fully elucidated. 
   Disruption of mitochondrial integrity and caspase-8 activation are one of the early 
events leading to apoptosis. It has earlier been elucidated that PPARγ synthetic ligands 
activate intrinsic and extrinsic apoptotic cascade [124,125]. To confirm the effects of 
down regulation of PGK1 and PKM2 on cell survival, I undertook analysis for caspase 
8 expression, mitochondrial membrane potential and nuclear damage. It was observed 
that activation of PPARγ causes caspase-8 activation (decrease in caspase-8 proenzyme 
expression). This data demonstrates that the caspase-8 proenzyme is being cleaved to 
active caspase-8 fragments in dose dependent fashion of 15d-PGJ2 (Figure 2-10). 
Apoptosis leads to activation of series of biochemical events that alter cell 
characteristics. One of these important changes is chromatin condensation and nuclear 
frag- mentation. To further examine these changes, I stained the nucleus with nucleic 
acid specific stain Hoechst stain. Figure 2-11 clearly presents the increase in condensed 
nuclei (apoptotic cells) in dose-dependent fashion. Also the MDA-MB-231 apoptotic 
cells were greater in number as compared to that in MCF-7 accounting for its higher 
basal level of PPARγ expression. 
      I next examined whether PPARγ activation causes mitochondrial damage by 
analyzing mitochondrial membrane potential with mitochondria fluorescent dye JC-1. A 
cationic dye that exhibits potential-dependent accumulation in mitochondria, indicated 
by a fluorescence emission shift from green (525 nm) to red (590 nm), JC-1 is most 
widely employed in detection of mitochondrial depolarization during early apoptosis, 
hallmarked by loss of mitochondrial membrane potential, coinciding with caspase 8 
activation. In non-apoptotic cells, JC-1 exists as a monomer in the cytosol (green) and 
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accumulates as aggregates in the mitochondria, which appear red. In apoptotic and 
necrotic cells, less dye accumulates in the mitochondria, and more is retained in the 
cytoplasm, hence more green and less red is visible. As shown in Figure 2-12, in the 
control cells with high mitochondrial membrane potential, the JC-1 dye formed J-
aggregates with intense red fluorescence. On the other hand, on treatment with 10 µM 
15d-PGJ2 there was progressive loss of red J-aggregate fluorescence and increased 
cytoplasmic diffusion of green monomer fluorescence, depicting disruption of 
mitochondrial potential. Together, these data demonstrate the activation of caspase-8, 
disruption in mitochondrial potential and chromatin condensation upon PPARγ 
activation leading to apoptotic cascade activation. 
 
2.4 CONCLUSION 
      My results have established previously unknown novel crosslink between PPARγ 
and glycolysis via PGK1 and PKM2; thereby adding a new dimension to therapeutic 
potential of PPARγ ligands. Although the exact mechanism remains unclear and further 
studies are still needed to clarify the potential role and molecular basis of action of 
PPARγ in breast carcinogenesis, my investigation open a new direction for development 
of novel therapeutic method by targeting PGK1 and PKM2 in breast cancer treatment 
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Table 2-1: List of putative PPARγ targets involved in breast cancer 
pathophysiology (PGK1 and PKM2 are putative PPARγ targets) 
ABCA1 COL18A1 HLA-B MXD1 RAB6A 
ABL1 COL1A2 HLA-C MYCBP RCAN1 
ACADM CREB1 HMGB1 MYCN RET 
ACE CRX HOXC9 MYOD1 RNPC3 
ADAMDEC1 CSE1L HPX NAMPT RPA1 
ADSL CXCL2 HRG NES RPS6KA1 
AKAP12 CXCR3 HSPA4 NF1 S100A9 
ALOX15 CXCR5 IFNGR2 NOS3 SCARB1 
APC CYCS IGFBP5 NOX1 SCP2 
APOC3 CYP21A2 IKBKB NR0B2 SEMA5A 
APOE DAZAP1 IKBKE NRG1 SERPINE1 
ARHGEF6 DDIT3 IL10RA NTRK1 SFRP4 
ASS1 DDR1 IL11 OPRM1 SLC11A2 
AVP DDR1 IL13RA1 OXER1 SLC2A2 
BACE2 DKK1 IL1RN PARK7 SLC9A2 
BBS2 DLG3 IL4 PARP4 SOD2 
BCL10 DNMT3B ILK PARVB SPAG5 
BCL2L1 DPP4 INS PCNT SSBP3 
BIRC3 DUSP13 INSL3 PDCD1LG2 ST6GAL1 
BRCA1 DYSF INSR PDE5A STAP1 
CA9 EIF2AK2 IRF5 PER2 STC2 
CALCR EIF2C1 IRF7 PGK1 TAC1 
CALM2 EPHB3 ITCH PIK3C2B TACC3 
CALM3 EWSR1 ITGA3 PIK3CA TAT 
CAMK2D EZR ITGB4 PKM2 TBP 
CAMP F2R JUB PKP1 TERF2 
CASP14 FBL KCNN3 PLAU TFRC 
CBX5 FBXW7 KIF11 PLAUR TGFA 
CCL20 FCGR2A KLRD1 PLCG1 TH 
CCNB1 FGF8 KRIT1 POLD4 TIMP1 
CD1C FGFR2 LCK POLR2L TLR4 
CD27 FKBP5 LGR6 PPA1 TMPO 
CD3D FLT1 LSM2 PPARA TMSB10 
CD80 FUT4 LTBR PPP2R2B TNC 
CD86 GATA3 MAD1L1 PRG2 TNFRSF1A 
CDC25C GHRL MAP1B PRKCD TNFRSF6B 
CDC34 GJC1 MAP2K7 PRKCG TNNI2 
CDK7 GLS MAP3K14 PRNP TPO 
CDK9 GNA15 MAPK1 PSMB5 UGT1A7 
CDS1 GNB1 MAPK10 PTGER3 VAV3 
CENPF HDAC3 MDM4 PTN WFDC2 
CFTR HEY1 MEN1 PTPN6 WNT3A 
CHEK1 HIPK2 MET PTPRA XRCC6 
CHKB HK1 MIF PXN YWHAH 
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Table 2-2:  Network parameters for top 20 PPARγ regulated genes involved in 
Breast cancer pathophysiology. 
 
Gene Name Node degree Betweenness Stress 
BRCA1 238 844494.11 5520696 
TERF2 191 688999.13 3567270 
HDAC3 184 389054.34 3237646 
YTHDC1 172 447848.96 0 
SP1 171 346739.49 2519974 
AKT1 125 344673.91 2539832 
ERCC2 117 442363.28 132142 
DEF1 116 312543.31 0 
ABL1 106 221707.21 1373642 
H2AFX 101 193243.75 181736 
PLCG1 93 233214.41 1115962 
ITCH 81 221022.57 1293228 
CREB1 74 154538.71 1058272 
MYOD1 73 132531.74 1030916 
EZH2 71 118931.96 658402 
RPA1 66 131552.69 799232 
VCP 66 217296.63 1036336 
BCL2L1 59 159560.98 1044134 
PRKCZ 56 136275.83 870684 
 
Average: 3.7 Average: 6242.74 Average: 46561.29 
 
Max: 238 Max: 844494.11 Max: 5520696 
 
Min: 1 Min: 0 Min: 0 
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Table 2-3: List of diseases associated with the genes possibly regulated by PPARγ 
and involved in breast cancer pathophysiology, detected by connectively and 
centrality parameters (node degree, betweenness, and stress) using Disease-
Ontology Lite (DoLite). 
 
 
Disease name Node Degree Betweenness Stress 
 
Cancer  33 4620.93 68152 
Breast cancer  18 1272.90 15444 
Prostate cancer  16 1484.50 18790 
Diabetes mellitus  15 1313.39 24032 
Rheumatoid arthritis  13 1150.80 17250 
Atherosclerosis  12 979.75 12622 
Embryoma  12 905.12 16224 
Colon cancer  11 998.42 19908 
Alzheimer's disease 10 633.48 11036 
Asthma  9 773.96 532 
 
Average: 4.55  Average: 272.47  Average: 4616.38  
 
Max: 33  Max: 4620.93  Max: 68152  
 Min: 1  Min: 0  Min: 0  
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Table 2-4: List of highly connected genes associated with the genes that are 
possibly regulated by PPARγ and involved in breast cancer pathophysiology, 
detected by connectivity and centrality parameters (node degree, betweenness and 
stress) using Disease-Ontology Lite (DOLite). 
 
Gene name Node degree Betweenness Stress 
SERPINE1  15 1818.93 33750 
IL1A  10 833.54 16768 
MIF  10 561.79 9760 
APOE  9 646.21 11220 
AKT1  8 825.62 15534 
EGR1  7 925.69 16434 
SOD2  7 601.33 9782 
TNC  7 414.27 5494 
BCL2L1  6 633.33 9746 
SMAD3  6 316.71 4858 
 
Average: 4.55 Average: 272.47 Average: 4616.38 
 
Max: 33 Max: 4620.93 Max: 68152 
 
Min: 1 Min: 0 Min: 0 
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Figure 2-1: Flow chart depicting a simplified scheme of the methodology used for 
identification of PPARγ target genes that are associated with breast cancer. The 
effects of the glycolytic pathway genes PGK1 and PKM2 were studied using molecular 
and biochemical methods.  
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Figure 2-2: PPARγ disease gene network associated with breast cancer. Top 20 
highly connected genes are shown in red and labeled. Genes chosen for experimental 
validation are labeled in pink. 
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[C] 
        
Figure 2-3: Classification of PPARγ target genes that are associated with breast 
cancer pathophysiology according to Gene ontology biological terms; Molecular 
function [A], Biological process [B] and Cellular component [C]. 
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Figure 2-4: DOLite analyses for PPARγ target genes that are associated with 
breast cancer. Top 10 diseases are shown in yellow triangle and top 10 genes are 
shown in green circles. 
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Figure 2-5:  Cell viability in breast cancer cell lines, MDA-MB-231 and MCF-7 
upon exposure to different doses of 15d-PGJ2 concentrations for 48 h. Data are 
presented as mean ± SEM of 3 independent experiments done in triplicates. ‘*’ 
(p<0.001).  
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Figure 2-6: Representative immunoblots for constitutive expression levels of 
peroxisome proliferator-activated receptor γ (PPARγ) in MDA-MB-231 and MCF-
7 [A]. [B] Quantitation of expression level in both breast cancer cells relative to β-actin 
is shown. Peroxisome proliferator-activated receptor γ (PPARγ) expression in MDA-
MB-231 was 2.4-folds higher than MCF-7 in presence of 15d-PGJ2. 
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Figure 2-7: Representative western blots for protein PGK1 in (A) MDA-MB-231 
and (B) MCF-7. (C, D) represents expression level of PGK1 in MDA-MB-231 and 
MCF-7 after 48 h of 15d-PGJ2 exposure. There was statistically difference of ‘**’ 
(p<0.005) between control and test groups. Data are presented as mean ± SEM of three 
independent experiments. 
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Figure 2-8: Representative western blots of PKM2 for (A) MDA-MB-231 and (B) 
MCF-7. Histograms (C, D) presenting expression level of PKM2 in MDA-MB-231 and 
MCF-7, respectively upon 48 h treatment of 15d-PGJ2. ‘**’ (p<0.005) represents 
statistically difference between control and test groups. Data are presented as mean ± 
SEM of three independent experiments done. 
 
 
 
	   46	  
 
[A]           
          
[B] 
 
 
 
Figure 2-9: ATP depletion upon peroxisome proliferator-activated receptor γ 
(PPARγ) activation in (A) MDA-MB-231 and (B) MCF-7. Data are presented as 
mean ± SEM of thee independent experiments. ‘*’  (p < 0.001) and ‘**’ (p<0.005)  
represents statistically difference between control and test groups. 
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Figure 2-10: Representative western blots of proenzyme caspase-8 for (A) MDA-
MB-231 and (B) MCF-7. (C, D) Histograms represent caspase-8 proenzyme’s 
expression level in MDA-MB-231 and MCF-7, respectively upon 48 h treatment of 
15d-PGJ2. Data are presented as mean ± SEM of three independent experiments. ‘**’ (p 
< 0.005) represents statistically difference between control and test groups.  
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Figure 2-11: Hoechst staining of the (A) MDA-MB-231 and MCF-7 breast cancer 
cell lines. (B) Histogram represents the percentage (mean ± SEM) of apoptotic cells in 
MDA-MB-231 and MCF-7. Significant difference of ‘*’ (p < 0.001) was observed in 
test groups of both cell lines as compared to control. Arrows indicate apoptotic cells. 
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Figure 2-12: Disruption of mitochondrial membrane potential upon peroxisome 
proliferator-activated receptor γ (PPARγ) activation in (A) MDA-MB-231 and (B) 
MCF-7 breast cancer cell lines [JC-1 (a), Phase (b), JC-1 active mitochondria (c), 
Merge (d)]. The cells were treated with 10 µM concentration of 15d-PGJ2 for 48 h and 
stained with JC-1 dye. Untreated cells showed strong J-aggregrates of JC-1 dye and 10 
µM 15d-PGJ2-treated cells showed majority of the cells stained in green due to loss in 
mitochondria membrane potential.  
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CHAPTER 3 
 
COFFEE COMPONENT HYDROXYL HYDROQUINONE (HHQ) 
AS A PUTATIVE LIGAND FOR PPAR GAMMA AND 
IMPLICATIONS IN BREAST CANCER 
 
3.1  INTRODUCTION 
      Coffee is one of the most widely consumed beverages in the world. The health-
promoting properties of coffee are often attributed to its rich phytochemistry, including 
caffeine, chlorogenic acid, caffeic acid, hydroxyl hydroquinone (HHQ), etc. More 
recently, coffee consumption has been associated with reductions in the risk of several 
chronic diseases, including type 2 diabetes mellitus, Parkinson’s disease and 
hepatocellular disease [126-128]. The association between coffee intake and breast 
cancer risk is biologically plausible because of its complex make-up of chemicals, e.g., 
caffeine and polyphenolic compounds such as flavonoids and lignans [129-131]. 
Among them, the relationship between coffee drinking and breast cancer risk holds 
great interest. Recent meta-analyses demonstrate inverse associations between coffee 
intake and the risk of colon, liver, breast, and endometrial cancer [132-135]. Also, a 
high daily intake of coffee has recently been reported to be associated with a statistically 
significant decrease in ER-negative breast (ER - Estrogen Responsive) cancer among 
postmenopausal women [136]. A number of previous epidemiologic studies have 
estimated the association between coffee consumption and breast cancer risk. However, 
the results are inconsistent [137]. Nevertheless, several reports in literature suggest 
that coffee consumption reduces the risk of cancer, but the molecular mechanisms of its 
chemopreventive effects remain unknown. Moreover, the interpretation of these data 
has often been limited to the role that caffeine plays [138,139].  
       HHQ is a natural constituent of coffee accounting for main dry matter constituent in 
roasted beans. Studies exploring the effects of this bioactive compound on mammalian 
cells are limited. HHQ was observed to dock and form hydrogen bonds with PDB ID - 
2PRG (PDB 3-D crystal structure of the Ligand-binding domain of the human 
peroxisome proliferator activated receptor gamma solved in complexation with 
Rosiglitazone, the PPAR gamma agonist/ligand). The initial purpose of our 
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investigation is to determine whether HHQ alters the cell viability in estrogen dependent 
human breast cancer (MCF-7) and estrogen independent (MDA-MB-231) cells as a 
model system. HHQ was observed to decrease cell viability and colony formation in a 
dose-responsive manner and ROS was found to significantly increase in HHQ treated 
cells in a dose-dependent manner in both the cell lines.  
 
3.2      EXPERIMENTAL SECTION  
3.2.1 COMPUTATIONAL METHODOLOGY 
Docking of HHQ into PPARγ structure  
       Docking studies were carried out using MolDock™ (Molegro virtual docker)  
which is based on a new heuristic search algorithm that combines differential evolution 
with a cavity prediction algorithm. The PDB file for the crystal structure of PPARγ 
(PDB ID - 2PRG) was downloaded from http://www.rcsb.org and transferred into the 
workspace keeping the orientation as a control. The energy between the existing ligand 
and protein was subsequently minimized. Both protein and ligands (Rosiglitazone and 
HHQ) were optimized in the workspace for docking by the addition of hydrogens. All 
structural water molecules were removed from the protein molecules using protein 
preparation wizard. Binding sites in the electrostatic surface of the protein was 
identified using the grid based cavity prediction algorithm. A total of five cavities were 
detected and the prepositioned ligand in the active site cavity was identified and the 
docking was constrained to the predicted active site cavity. MolDock™ scoring function 
is used for evaluating the energy between the ligand and the protein target. Grid 
resolution, number of runs, population size, maximum iterations, scaling factor, and 
cross over rate were set as 0.30 Å, 10, 50, 2000, 0.5, 0.9, respectively, for each run. 
Multiple poses were returned for each run with the RMSD threshold set to 1.00 Å. The 
pose with the highest rerank score was retained in the workspace for detailed evaluation 
of the ligand binding at the active site cavity. MVD was installed in Windows vista 
operating system on an Intel Core 2.  
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3.2.2    EXPERIMENTAL VALIDATION METHODOLOGY 
Reagents 
       Dulbecco’s modified eagle’s medium (1000 mg/L glucose, L-glutamine and sodium 
bicarbonate), Fetal bovine serum, HHQ, GW9662 and crystal violet were purchased 
from Sigma-Aldrich (St Louis, MO, USA). Penicillin–Streptomycin–Neomycin 
antibiotic mixture, Hoechst 33258 and the Image-iTTM LIVE Green Reactive Oxygen 
Species (ROS) detection reagents were procured from Invitrogen (Eugene, OR, USA) 
and JC-1dye from Biotium (Hayword, CA, USA). Sodium chloride, Tris base, 
potassium chloride, sodium di hydrogen phosphate, glycine and sodium phosphate di 
basic were purchased from Wako Pure Chemical Industries (Osaka, Japan). 
Cell culture and treatments 
       The human breast adenocarcinoma cell lines MCF-7 and MDA-MB-231 were 
purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA). 
The carcinoma cultures were maintained in Dulbecco’s modified eagle’s medium 
supplemented with 10% fetal bovine serum and PNS antibiotic mixture 100 ng/mL at 
37°C and 5% CO2/95% O2. Cultures at about 50% confluency were treated with 12.5 
µM and 25 µM of HHQ concentration for 48 h at 37°C and for PPARγ activity 
inhibition studies, the breast cancer cells were pre-treated with GW9662 (10 µM, 4 h at 
37°C) followed by HHQ (12.5 µM and 25 µM, 48 h at 37°C) and harvested for further 
use.    
Cell Proliferation Assay and Morphological Study 
      HHQ was tested for its anti-proliferative activity on MDA-MB-231 and MCF-7 
cells using the 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromides (MTT) 
test (Roche, Mannheim, Germany) following manufacturer’s instructions. The MTT 
metabolic activity is a colorimetric cell proliferation assay that identifies living cells, 
and is based on the cellular conversion of a tetrazolium salt into insoluble formazan, 
which can be quantified by spectrophotometry. 5 x 103 cells/ well were plated in 96-well 
plates and grown for 24 h. The cells were then exposed to varying concentrations of 
HHQ for 48 h to find the half maximal inhibitory concentration (IC-50) values. The 
intensity of the reduced dye that corresponds to the viable cells was measured at 
reference wavelength of 570 nm by Thermo Scientific Varioskan Flash Multimode 
Reader. Morphological changes in breast cancer cells treated with 12.5 µM and 25 µM 
of HHQ concentration for 48 h were examined by phase contrast microscopy. All 
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experiments were performed in triplicates, and the relative cell viability (%) was 
expressed as a percentage relative to the untreated control cells.  
Clonogenic assay 
       Colony formation potential of human breast cancer cells on exposure to HHQ was 
assessed by clonogenic assay. Clonogenic assay is a cell survival assay based on the 
ability of a single cell to grow into a colony. To determine long-term effects, breast 
cancer cells were treated with 12.5 µM and 25 µM of HHQ concentration for 48 h. At 
the end of treatment the breast cancer cells were then plated at a concentration of 100 
cells/well in a new 6-well plate. The cells were allowed to grow for 14 days to form 
colonies. Fresh medium was replaced every third day. The colonies were washed with 
PBS and fixed in pre-chilled methanol: acetone mixture (1:1) for 10 min at room 
temperature. The colonies were then stained with crystal violet dye (0.5% in water) at 
room temperature for overnight. Cells were washed with water and plates were 
photographed with image scanner (EPSON GT-1500).  Quantitative analysis of the total 
number of colonies was performed with Image J software (National Institutes of 
Health). 
Detection of reactive oxygen species 
      The reactive oxygen species were detected by fluorescent staining using the Image-
iTTM LIVE Green Reactive Oxygen Species (ROS) Detection Kit (Molecular Probes 
Inc, USA). The assay is based on a nonfluorescent and cell permeable 5-(and-6)-
carboxy-2’,7’-dichlorodihydrofluorescein diacetate (carboxy-H2DCFDA). The carboxy-
H2DCFDA permeates the live cells and is deacetylated by intracellular esterases. The 
reduced fluorescein compound is oxidized by the cellular ROS and emits bright green 
fluorescence with excitation/ emission maxima of 495/529 nm. The cells were grown on 
glass cover slips placed in 12-well plate and were treated with 12.5 µM and 25 µM 
concentration of HHQ for 48 h. Subsequently, cells were fixed and then stained for ROS 
by following manufacturer’s instructions. The images were analyzed with AxioVision 
software (version 4.4, Carl Zeiss).  
 
Assessment of mitochondrial membrane potential  
       Mitochondrial transmembrane potential was investigated using a fluorochrome, JC-
1 dye (Biotium). JC-1 (5,5’,6,6’-tetrachloro-1,1’,3,3’ tetra ethyl benzimidazolyl carbo 
cyanine iodide) dye exhibits potential-dependent accumulation  of red fluorescent J-
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aggregates in energized  mitochondria. JC-1 exists as a green fluorescent (535 nm) 
monomer and also accumulates as J-aggregates (595 nm) in the active mitochondria, 
which stain red. Consequently, healthy cells will exhibit high red/green fluorescence 
intensity ratio.  In apoptotic cells, mitochondrial depolarization is indicated by a 
decrease in the red/green fluorescence intensity ratio. Therefore this fluorescence 
emission shift from green (~529 nm) to red (~590 nm) is indicative of mitochondrial 
depolarization occurring during apoptosis. After 48 h of 12.5 µM and 25 µM of HHQ 
treatment, the cells were incubated with 1X JC-1 dye at 37°C for 15 min followed by 
washes with assay buffer. The red fluorescence (excitation 550 nm, emission 600 nm) 
and green fluorescence (excitation 485 nm, emission 535 nm) were measured using 
fluorescence Thermo Scientific Varioskan Flash Multimode plate reader. The ratio of 
red fluorescence to green fluorescence was determined in JC-1 stained cells. The 
relative mitochondrial membrane potential (%) was expressed as a percentage relative 
to the untreated control cells. 
Immunocytostaining 
      In order to find out the modulation of test proteins by HHQ through PPARγ, the test 
protein were immunostained. For immunostaining, cells were plated on glass coverslips 
in a 12-well plate (104 cells/coverslip). The cells were allowed to attach for 24 h and 
then exposed to 12.5 µM and 25 µM of HHQ for 48 h. At the end of treatment cells 
were washed with cold PBS three times and then fixed with pre-chilled methanol: 
acetone mixture (1:1) for 10 min at room temperature. Fixed cells were washed twice 
with PBS, permeabilized with 0.32% Triton X-100 in PBS (PBST) for 10 min and 
blocked with 2% bovine serum albumin (BSA) in PBS for 30 min. The cells were then 
probed with anti-PGK1 (1:250; Abcam, Cambridge, UK), anti-PKM2 (1:250; Abcam, 
Cambridge, UK), antibodies for overnight at 4°C.  After primary antibody incubation 
the cells were washed thrice with 0.1% PBST, and then incubated with secondary 
antibodies (Alexa-594-conjugated goat anti-rabbit and Alexa 488-conjugated goat anti-
mouse, (Molecular Probes, Eugene, OR) for 1 h at room temperature followed by 3 
times washing with 0.1% PBST and then once with PBS. The coverslips were then 
mounted with ProLong+® Gold antifade reagent (Molecular Probes, Inc.) and observed 
under a microscope (Axiovert 200M; Carl Zeiss, Thornwood, NY). The experiment was 
carried out in duplicate in three independent experiments.  The images were analyzed 
with Axio Vision software (version 4.4, Carl Zeiss).  
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Western blot analysis 
       Expression level of indicated proteins was examined by Western blotting. The 
control and treated cells were lysed in RIPA lysis buffer (25 mM Tris–HCl (pH 7.6), 
1% NP-40, 1% sodium deoxycholate, 150 mM NaCl, 0.1% SDS) complemented with 
complete protease inhibitors (Roche) for 15 min on ice followed by centrifugation at 
14,000 g for 15 min at 4°C. The protein concentration was determined using BCA 
reagents (Pierce, Rockford, IL, USA). Protein lysate (20 µg) was resolved in 10% in 
SDS-polyacrylamide gel under standard denaturing conditions according to Laemmli’s 
method (1970) followed by transfer onto polyvinylidene difluoride membranes using a 
Trans-Blot SD (Bio-Rad, Lewes, E. Sussex, UK.) semi-dry electroblotter for 30 min at 
20 V. Subsequently, the membranes were blocked for 45 min at room temperature with 
2% bovine serum albumin in 0.1% PBST. The membranes were then probed with anti-
PGK1 (1:1000; Abcam, Cambridge, UK), anti- PKM2 (1:500, Abcam), anti-caspase-8 
(1:1000; Cell Signaling, Boston, MA, USA), Anti-Bax (1:1000; Cell Signaling) and 
anti-β-actin (1:20,000; Abcam) at 4°C overnight followed by three washes for 5 min 
each with 0.1% PBST. The membranes were then incubated with horseradish 
peroxidase conjugated secondary antibody (1:20,000; Abcam) for 45 min at RT and 
washed thrice for 5 min each with 0.1% PBST followed by chemiluminescent detection 
using Luminescent Image Analyzer equipped with charge-coupled device camera (LAS-
4000 Ver. 2.1; Fuji Film, Tokyo, Japan). 
Data Analysis 
      The captured images for ROS assay and immunostaining were analyzed using 
AxioVision software (version 4.4; Carl Zeiss). The analysis determined the overall 
density of ROS, PGK1 and PKM2 immunoreactivity in 5-8 randomly selected fields in 
each slide. The mean intensity of ROS, PGK1, and PKM2 immunoreactivity in control 
and treated cells were evaluated and presented as a histogram. Similarly the Relative 
Optical Density (%) for immunoreactive bands in western blotting for PGK1, PKM2 
and Caspase-8 were analyzed using Image J software (National Institutes of Health).  
 Statistical Analysis 
     The quantitative data are representative of three independent experiments done in 
triplicates and expressed as mean ± SEM. Statistical analysis was performed using 
analysis of variance (one way analysis of variance) followed by Bonferroni’s on test to 
determine differences in mean and p < 0.05 was considered as statistically significant. 
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3.3   RESULTS AND DISCUSSION  
      Understanding the molecular pathways that link tumor biology to the staggering 
array of pathologies and genes is of paramount scientific and medical importance. 
Though, the complexity of the underlying biochemical and molecular mechanisms of 
breast cancer make metabolic reprogramming and transformation in breast cancer 
unclear, many dietary compounds have been identified as potential chemopreventive 
agents. PPARγ is an interesting target for cancer therapy as its expression is elevated in 
tumors and also because PPARγ activation is reported to result in decreased cell 
proliferation, decreased G0/G1 to S phase progression, apoptosis and increased terminal 
differentiation [140-142].  Also, imbalances in expression of target genes forms the core 
of metabolic syndrome and cancer regulation through atherogenic metabolic triad/lipid 
triad metabolism modulation by PPARs [143]. Concurrently, increased levels of 
glycolytic proteins are observed in plasmas of women with breast cancer as a result of 
upregulation of glycolysis pathway [144].  
     In this paper, I for the first time report on the use of coffee component HHQ as a 
potential ligand for PPARγ and its role in induction of apoptosis in breast cancer cells 
by delineating the glycolytic pathway gene regulation by PPARγ activation. 
3.3.1  Docking 
      The three-dimensional protein structures can be used to understand ligand binding 
and to rationally design novel ligands as prospective drug compounds. PPAR agonists 
typically possess a small polar region and a hydrophobic region that form hydrogen 
bonds and hydrophobic interactions, respectively, within the ligand binding 
domain.  Several crystal structures of PPARγ in complexation with their ligands are 
available in the protein data bank (PDB). Here, I used the PDB crystal structure 2PRG 
(PPARγ with ligand Rosiglitazone) for structure-based identiﬁcation of HHQ as a 
potential ligand for PPARγ in breast cancer therapeutics. I also compared the ligand 
binding properties of the two compounds Rosiglitazone (the known ligand) and HHQ 
(the proposed novel ligand). The rerank scores for the Rosiglitazone and HHQ were 
found to be -122.433 and -33.3562, respectively. The hydrogen bond energy values 
were -5.487 kcal/mol, and -9.460 kcal/mol for Rosiglitazone and HHQ. Rosiglitazone 
(the ligand in the crystal structure 2PRG) forms 3 hydrogen bonds with the 2PRG 
(Gln286, His449, Ser289) and HHQ forms 5 hydrogen bonds with 2PRG (Gln286, 
His449, Tyr473, Ser289, His323). Hydrogen bonding of the ligand to Tyr473 is 
	   57	  
reported to be the key to the stabilization of the AF-2 region and it has also been shown 
that [145] agonistic activity of ligands disappears when Tyr473 is mutated. The 
importance of His323 and His449 has also been reported [146,147]. Our results show 
that both the ligands have hydrogen bond interactions with key residues - Tyr473 and 
His 449, thereby providing specificity of interaction that is a fundamental aspect of 
molecular recognition. The active site residues that interact with HHQ are shown in 
Table 3-1 and the hydrogen bonds between each compound and the 2PRG active site are 
shown in Figure 3-1. 
3.3.2 HHQ inhibits cell proliferation and clonogenic survival  
              To investigate the potential cell growth inhibition of HHQ, I first examined the 
effect of HHQ on cell proliferation and clonogenic survival in human breast 
adenocarcinomas. I chose two breast adenocarcinoma cell lines, MDA-MB-231 
(estrogen independent) and MCF-7 (estrogen dependent). MDA-MB-231 and MCF-7 
were cultured in the control medium for 24 h, followed by 48 h treatment with different 
concentrations of HHQ for cytotoxic and anti-proliferative studies. HHQ led to decrease 
in relative density of viable cells as detected by MTT dye reduction assay. A dose-effect 
relationship was observed as shown in Figure 3-2. The IC-50 value for MDA-MB-231 
and MCF-7 were found to be 25 µM and 50 µM, respectively. I proceeded with 12.5 
µM and 25 µM of HHQ to investigate the comparable effects of same concentration on 
both the cell lines. At 12.5 µM the relative viability in MDA-MB-231 and MCF-7 was 
58.2% and 76.3%, respectively, whereas at 25 µM the relative viability in MDA-MB-
231 and MCF-7 was 50% and 60.7%, respectively. As morphological analyses depict 
the health of a cell, I next examined the cells for any altered morphology on treatment 
with HHQ. Cells cultured in the presence of HHQ (12.5 µM and 25 µM) show 
significant morphological changes and were found to be reduced in cell mass as well as 
number as compared to control (Figure 3-3). Also, HHQ treatment induced detachment 
and rounding in breast cancer cells as shown by phase contrast images in both the cell 
lines  (12.5 µM and 25 µM). Furthermore, to examine the antitumor activity of HHQ on 
colony forming potential in breast cancer cells I performed clonogenic assay. This assay 
is an in vitro assay based on the ability of a single cell to proliferate and differentiate 
into colonies in response to various insults. HHQ severely affected the colony forming 
potential of human breast cancer cells - MDA-MB-231 and MCF-7. As shown in Figure 
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3-4, clonogenicity of both the breast cancer lines were found to be significantly reduced 
in a concentration-dependent manner after exposure to HHQ.  
3.3.3  HHQ induces intracellular ROS generation and cytotoxicity 
      Reactive oxygen species (ROS) is a universal entity mediating apoptosis [148]. ROS 
act as a secondary messenger in cell signaling and are essential for various biological 
processes in normal cells. Disturbances in redox balance relate to human pathogenesis 
including cancers. ROS are constantly generated and eliminated in the biological 
system, and play important roles in a variety of normal biochemical functions and 
abnormal pathological processes. Growing evidence suggests that cancer cells exhibit 
increased intrinsic ROS stress, due in part to oncogenic stimulation, increased metabolic 
activity, and mitochondrial malfunction. Since ROS are chemically active and can 
inflict severe cellular damage, the very fact that cancer cells are under increased 
intrinsic ROS stress may also provide a unique opportunity to kill the malignant cells 
based on their vulnerability to further ROS insults caused by exogenous agents [149]. 
HHQ is earlier reported to generate reactive oxygen species (ROS) by autoxidation 
[150]. 
      Therefore, to get further insights to HHQ induced cytotoxicity in breast cancer cells; 
I examined the intracellular ROS generation.  As shown in Figure 3-5, intracellular ROS 
formation was found to be significantly increased in HHQ treated cells as compared to 
control cells in a dose-dependent manner. The effective enhancement of ROS 
production by HHQ correlates to its cytotoxicity nature.  Since the mitochondrial 
respiratory chain (electron transport chain) is a major source of ROS generation in the 
cells, the vulnerability of the mitochondrial DNA to ROS mediated damage has been 
suggested to be a mechanism to amplify ROS stress in cancer cells [151]. One major 
effect is to generate increased intracellular ROS causing loss of outer mitochondrial 
membrane permeability and induction of apoptosis [152,153].  Another possible 
mechanism by which cancer cells generate increased amounts of ROS may involve 
malfunction of the mitochondrial respiratory chain. The fact that cancer cells exhibit an 
increased dependency on glycolysis to meet their ATP need (the Warburg effect) may 
reflect an inefficient ATP generation in mitochondria, or “respiration injury” [154]. A 
correlation between mtDNA mutations and increased ROS contents in primary leukemia 
cells isolated from patients has been shown [155]. Because the mitochondrial 
respiratory chain is the major site of ROS generation due to electron transfer, 
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malfunction of the mitochondrial respiratory chain associated with mtDNA mutations is 
likely to result in more free radical production due to increased “leakage” in 
mitochondrial membrane. 
3.3.4 HHQ induces mitochondrial dysfunctioning  
      Mitochondria are central players in the determination of cell life and death. Their 
main physiological function is energy production by the oxidative phosphorylation 
pathway. This process not only involves production of cell energy currency, ATP but 
also increases the production of reactive oxygen species (ROS) as by-products of 
aerobic metabolism. Mitochondria are also the main regulators of apoptotic cell death 
by mediating extrinsic and intrinsic apoptotic pathways. Oxidative stress may cause 
oxidative damage to various cellular components and may lead to lipid peroxidation, 
protein oxidation, mitochondrial DNA mutations, initiation of apoptosis cascade by 
decrease in mitochondrial membrane potential and release of apoptogenic factor 
cytochrome c into the cytosol  [156].  Thus, the oxidative damage and the associated 
mitochondrial dysfunction may lead to energy depletion, accumulation of cytotoxic 
mediators, apoptosis and ultimately cell death.   
      Therefore to investigate the effect of HHQ induced oxidative stress on mitochondria 
and apoptosis cascade initiation, I undertook mitochondrial membrane potential analysis 
using potential sensitive, cationic dye JC1. This dye exhibits potential-dependent 
accumulation in mitochondria, indicated by a fluorescence emission shift from green 
(525 nm) to red (590 nm). Consequently, live cells have higher red/green intensity ratio 
as compared to cells undergoing apoptosis. As shown in Figure 3-6, I observed that the 
breast cancer cells when treated with HHQ show loss of mitochondria membrane 
potential (MMP) in a dose-dependent manner. This decrease in MMP at 25 µM of HHQ 
was significant in both the cell lines. Furthermore, I found that the level of pro-apoptotic 
protein Bax, significantly increased in a concentration-dependent manner in both the 
breast cancer cells (Figure 3-7). The expression levels of Bax correlates with the MMP 
loss in breast cancer cells on treatment with HHQ. This protein is involved in the 
mitochondrial apoptotic signaling pathway. The activation of the proapoptotic Bcl-2 
family member Bax, induces permeabilization of the mitochondrial outer membrane and 
release of cytochrome c leading to caspase dependent apoptosis [157,158]. Together, 
these data demonstrate that there is disruption in mitochondrial potential, permeability 
and functioning upon PPARγ activation by HHQ. 
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3.3.5     Induction of Caspase dependent apoptosis by HHQ  
       Caspase-8 activation is one of the early events leading to apoptosis. PPAR synthetic 
ligands are known to activate intrinsic and extrinsic apoptotic cascade [159,160]. In 
order to understand the mechanism of cell death, I hypothesized that PPARγ ligand 
HHQ may initiate apoptosis cascade via PPARγ dependent pathway.  To examine the 
above hypothesis I undertook the expression analysis of apoptotic protein, caspase-8. 
Interestingly, I observed that on treatment with HHQ the level of procaspase-8 
decreases significantly in both the cancer cells. This demonstrates that caspase-8 
proenzyme is being cleaved to active caspase-8 fragments in a dose-dependent manner 
(Figure 3-8). Concurrent increase in proapototic protein Bax, loss of mitochondrial 
membrane potential and activation of caspase-8 demonstrate PPARγ dependent 
apoptotic cascade activation by HHQ.  
3.3.6 PPARγ dependent modulation of glycolytic enzymes 
       In 1930, Otto Warburg discovered the unknown link between highly proliferative 
nature of cancer cells and glycolysis [91]. The phenomenon involved was described as 
the "Warburg Effect" which is characterized by increased glucose uptake and 
dependence on glycolysis for ATP production even in the presence of oxygen source. 
The glycolytic rate of rapidly proliferating tumor cells was found to be 200 times higher 
than those of their normal tissues of origin. Altenberg and Greulich (2004) found over 
expression of glycolytic genes in 24 different types of cancer including breast cancer. 
Two such glycolytic genes are phosphoglycerate kinase 1 (PGK1) and tumor specific 
pyruvate kinase muscle 2 (PKM2) [161,162]. PGK1 and PKM2 catalyze the sixth and 
ninth step, respectively, in the glycolysis pathway generating two ATPs each. PGK1 
also functions as a polymerase alpha cofactor protein (primer recognition protein) and is 
involved in DNA synthesis. PKM2 on the other hand is also a metabolic regulator and is 
also reported to be involved in channelization of glucose carbons to biosynthetic 
processes and hence control glycolysis. Hence, down regulating these enzymes would 
not only starve the cells for ATP but also lead to biosynthetic metabolite starvations, as 
they are important for tumor cell proliferation and survival. Earlier, I reported that both 
phosphoglycerate kinase 1 (PGK1) and pyruvate kinase M2 (PKM2) are repressed by 
PPARγ in the breast cancer cell lines MDA-MB-231 and MCF-7 [163]. Further analysis 
suggested that this repression leads to decrease in ATP levels and apoptosis. Here, I 
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hypothesized (based on docking results) that HHQ can modulate the expression of 
PGK1 and PKM2 via PPARγ dependent pathway.   
      Therefore, to test this hypothesis, I undertook expression analysis of these metabolic 
enzymes. I observed that the expression of glycolytic genes, PGK1 and PKM2 was 
significantly reduced in both the breast cancer cells on treatment with HHQ in dose-
dependent manner, (Figure 3-9 and 3-10). Further, to confirm the repression of 
glycolytic genes, PGK1 and PKM2 through HHQ induced PPARγ activation, I utilized 
GW9662, an irreversible PPARγ antagonist which acts by binding to the human ligand-
binding domain (region E/F). As shown in Figure 3-11, no significant repression of 
PGK1 and PKM2 was seen on pre-treating the breast cancer cells with GW9662 (10 
µM, 4h at 37°C) followed by HHQ (12.5 µM and 25 µM, 48h at 37°C). GW9662 
showed no effect of HHQ on expression of PGK1 and PKM2, thereby suggesting that 
the activation of PPARγ is required for repression of these enzymes.  Conversely, these 
data suggests that HHQ represses the expression of glycolytic enzymes via PPARγ 
dependent pathway. Down regulation of PGK1 and PKM2 decreases ATP production in 
the cytoplasm and mitochondria, initiating apoptosis and suppressing cancer 
metabolism.  ATP depletion, used in combination with chemotherapy and/or radiation, 
has a variety of effects on cancer cells including inducing apoptosis in multi-drug 
resistant cells and decreasing tumor promotion. Cellular ATP level has been reported as 
an important determinant of cell death [164]. Though the exact mechanisms of these 
effects have not been fully elucidated, these investigations suggest on the role of HHQ 
as an anti-cancer agent.  However, further work is required to establish the exact nature 
and behavior of this molecule in conjunction with other coffee components and to 
determine its relevance to the biological role of PPARγ breast cancer progression and 
therapeutics. 
 
3.4 CONCLUSION 
       My results have established previously unknown novel cross-link between HHQ, 
PPARγ, ROS and glycolysis; thereby adding a new dimension to therapeutic potential 
of PPARγ ligands. Although the exact mechanism remains unclear and further studies 
are still needed to clarify the potential role and molecular basis of action of PPARγ in 
breast carcinogenesis, my investigation open a new direction for development HHQ in 
breast cancer treatment. Further investigations on these could possibly help us in 
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understanding the molecular mechanisms by which PPARγ regulates disease targets 
specifically in breast cancer and the use of its ligands in breast cancer therapeutics. 
Despite several advancements that have been made on the subject, there is still much to 
be clarified regarding PPARγ signaling in breast cancer and several important questions 
remain unanswered. Many intriguing avenues of PPARγ research have been opened and 
hold the potential to ultimately lead to newer classes of more selective molecules. 
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Table 3-1: Docking results for HHQ and Rosiglitazone. 
 
Drugs 
 
 
Hydrogen bond 
score 
(kcal.mol-1) 
 
Number  of 
hydrogen 
bonds 
 
Residues of PPARγ 
binding site interacting 
with the ligands 
Rerank score 
 
 
HHQ 
 
-9.46033 
 
5 
 
Gln286, His449, Tyr473, 
Ser289, His323 
-33.3562 
 
Rosiglitazone -5.48771 3 Gln286, His449, Ser289 -122.433 
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Figure 3-1: HHQ docked in the ligand binding domain of PPARg protein crystal 
structure for PDB solved in conjunction with Rosiglitazone (PDBID: 2PRG). [A] 
Represents hydrogen bonds (in black dotted line) observed for Rosiglitazone (in red) 
with the active site residues in the ligand binding domain of PPARg (2PRG). [B] 
Represents hydrogen bonds (in black dotted line) observed for HHQ (in yellow) with 
the active site residues in the ligand binding domain of 2PRG. [C] Represents 
superposition of the best conformation of Rosiglitazone (in red) and HHQ (in yellow) 
in the ligand binding domain of 2PRG. [D] and [E] represents the  chemical bond 
between rosiglitazone and HHQ with 2PRG, respectively.  
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Figure 3-2:  Growth curve inhibition as assessed by MTT assay in human breast 
cancer cells (MDA-MB-231 (black line) and MCF-7 (grey line)). The breast 
cancer cells were exposed to different doses of HHQ for 48 h at 37°C. The cell 
viability in breast cancer cells decreased in dose-dependent fashion. The IC-50 value 
for MDA-MB-231 and MCF-7 were observed to be 25 µM and 50 µM, respectively. 
Data are representative of three independent experiments done in triplicates and 
expressed as mean ± S.E.M. ‘*’ (p < 0.005) represents statistical significant 
difference between control and HHQ test groups. 
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Figure 3-3: Phase contrast images of human breast cancer cells (MDA-MB-231 
and MCF-7). The breast cancer cells were exposed to 12.5 µM and 25 µM 
concentration of HHQ for 48 h at 37°C. HHQ treated groups did not retain their normal 
morphology. HHQ induced cell rounding and detachment in breast cancer cells. 
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Figure 3-4: The inhibitory effects of HHQ on colony formation in human breast 
cancer cells (MDA-MB-231 and MCF-7) as evaluated by clonogenic assay. The 
breast cancer cells were exposed to 12.5 µM and 25 µM concentration of HHQ for 48 h 
at 37°C. [A] Representative plates; [B] graph of the number of colonies formed (the 
result of three independent experiments, expressed as mean ± S.E.M). Decrease in 
number of colonies in HHQ treated groups were statistically significant ‘*’ (p < 0.005). 
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Figure 3-5: HHQ induced intracellular ROS production in human breast cancer 
cells, MDA-MB-231 [A] and MCF-7 [C]. The breast cancer cells were treated with 
12.5 µM and 25 µM of HHQ for 48 h at 37°C, intracellular ROS was detected by a 
fluorescent microscope. Quantitation of the ROS signals in MDA-MB-231 and MCF-
7 is shown in [B] and [D], respectively. Significant increase in ROS level was 
observed in HHQ treated cells. Data are representative of three independent 
experiments done in triplicates and expressed as mean ± S.E.M. Increase in ROS 
generation in HHQ treated groups with 12.5 µM and 25 µM were statistically 
significant ‘*’ (p < 0.005). 
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Figure 3-6: HHQ induced loss in mitochondrial membrane potential (MMP) in 
human breast cancer cells (MDA-MB-231 and MCF-7). The breast cancer cells were 
treated with 12.5 µM and 25 µM of HHQ for 48 h at 37°C and then immunostained for 
JC1. HHQ treated cells showed loss of MMP comparable to that of the control cells. Data 
are representative of three independent experiments done in triplicates and expressed as 
mean ± S.E.M. ‘*’ (p < 0.005) represents statistical significant difference between 
control and HHQ test groups. 
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Figure 3-7: Expression analyses of pro-apoptotic protein Bax in response to HHQ 
treatment in human breast cancer cells (MDA-MB-231 and MCF-7). The breast 
cancer cells were treated with 12.5 µM and 25 µM of HHQ for 48 h at 37°C. 
Representative western blot hybridization signals of Bax for MDA-MB-231 [A] and 
MCF-7 [B] and the quantitation of the signals is shown in [C] and [D], respectively. 
Significant increase in Bax expression was observed in HHQ treated cells. Data are 
presented as mean ± S.E.M. of three independent experiments. ‘*’ (p < 0.005)  
represents statistical significant difference between control and HHQ test groups. 
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Figure 3-8: Expression analyses of proenzyme caspase-8 in response to HHQ 
treatment in human breast cancer cells (MDA-MB-231 and MCF-7). The breast 
cancer cells were treated with 12.5 µM and 25 µM of HHQ for 48 h at 37°C. 
Representative western blot hybridization signals for proenzyme caspase-8 for MDA-
MB-231 [A] and MCF-7 [B] and the quantitation of the signals are shown in [C] and 
[D], respectively. Significant decrease in expression of proenzyme caspase-8 was 
observed in HHQ treated cells. Data are presented as mean ± S.E.M. of three 
independent experiments. ‘*’ (p < 0.005) represents statistically difference between 
control and HHQ test groups. 
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Figure 3-9: Expression analyses of glycolytic enzyme phosphoglycerate kinase 1 
(PGK1) in response to HHQ treatment in human breast cancer cells, MDA-MB-231 
and MCF-7. The breast cancer cells were treated with 12.5 µM and 25 µM of HHQ for 
48 h at 37°C. Representative western blot hybridization signals for PGK1 [A] and the 
quantitation of the signals is shown in [B]. Immunofluorescent detection of PGK1 is 
shown in [C] and the relative intensity measurement of immunofluorescence is shown in 
[D]. Significant decrease in PGK1 expression was observed in HHQ treated cells. Data 
are representative of three independent experiments done in triplicates and expressed as 
mean ± S.E.M.‘ ‘*’ represents the statistical significant (p<0.05) difference between 
control and HHQ treated group 
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Figure 3-10: Expression analyses of glycolytic enzyme pyruvate kinase-muscle 2 
(PKM2) in response to HHQ treatment in human breast cancer cell, MDA-MB-231 
and MCF-7. The breast cancer cells were treated with 12.5 µM and 25 µM of HHQ for 
48 h at 37°C. Representative western blot hybridization signals for PKM2 [A] and the 
quantitation of the signals is shown in [B]. Immunofluorescent detection of PKM2 is 
shown in [C] and the relative intensity measurement of immunofluorescence is shown in 
[D]. Significant decrease in PKM2 expression was observed in HHQ treated cells. Data 
are representative of three independent experiments done in triplicates and expressed as 
mean ± S.E.M. ‘*’ represents the statistical significant (p<0.05) difference between 
control and HHQ treated groups. 
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Figure 3-11: PPARγ dependent repression of glycolytic enzymes PGK1 and PKM2 
by HHQ in human breast cancer cells, MDA-MB-231 and MCF-7. The breast cancer 
cells were pre-treated with a potent PPARγ antagonist, GW9962 (10 µM) for 4 h at 37°C, 
followed by treatment with 12.5 µM and 25 µM of HHQ for 48 h at 37°C. Representative 
western blot hybridization signals for PGK1 [A] and PKM2 [B] for both the breast 
cancer cell lines and the quantitation of the signals is shown in [C] and [D], respectively. 
GW9662 showed no effect of HHQ on expression of PGK1 and PKM2, thereby 
suggesting that the activation of PPARγ is required for repression of these enzymes. Data 
are representative of three independent experiments and expressed as mean ± S.E.M. 
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CHAPTER 5 
 
5.1   CONCLUSION 
      The purpose of the present study was to identify novel transcriptional of nuclear 
hormone receptor - peroxisome proliferator activated receptor gamma (PPARγ) 
involved in breast cancer pathophysiology and functionally validate the identified 
PPARγ novel targets by its natural ligand 15-Deoxy-Δ12, 14-prostaglandin J (15d-
PGJ2) and PPARγ novel ligand/ activator (HHQ). 
     Chapter 1 focuses on the background of the research. A brief introduction to 
breast cancer burden in the world, current therapies for breast (radiation therapy, 
chemotherapy, endocrine therapy and surgery), reasons for need of alternate breast 
cancer therapy such as adverse effects of chemotherapy and radiation therapy, 
available drugs for breast cancer and the details of resistance acquired by breast 
cancer is discussed. Furthermore, role of PPARγ in tumorigenesis, its mechanism of 
action, known PPARγ ligands and its transcriptional targets are also discussed in 
detail.  
      In chapter 2, I computationally identified PPARγ binding motifs, PPRE and 
PACMs in the whole human genome by PPRE search tool.  A total of 217 genes 
were identified with PPRE and PACM sites involved in breast cancer 
pathphysiology. As complex global network of protein interactions dictates cellular 
behavior, therefore 217 putative PPARγ targeted breast cancer genes were mapped to 
the BioGRID to identify the their interacting partners and these protein interaction 
network were visualized by Cytoscape. The average value of the node degree, 
betweenness and stress was 3.7, 6242.74, and 46561.29, respectively. BRCA1 scored 
the highest for all the three centrality parameters Furthermore, the putative targets 
were mapped on to PANTHER database, to classify genes according to gene 
ontology classes: molecular function, biological process and cellular component.  
The analysis revealed that cell cycle (52), cell–cell signaling (30), and signal 
transduction (28) were the most common GO categories representing biological 
processes. A total of 280 classifications were identified under the molecular function 
with transcription factor activity, protein kinase activity, and transmembrane protein 
kinase activity in the top three. Further functional disease ontology was performed to 
find the enrichment of predicted PPARγ breast cancer target gene set in various 
disease profiles.  All the genes were found to be associated with diseases. The 
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disease gene network showed predominant role of PPARγ in cancer in general 
(18.5%), followed by breast cancer (10.1%), and prostate cancer (8.9%). Cancer and 
SERPEINE had the highest centrality pararaeters in protein–protein interaction 
network disease and gene network. Also based on the protein and protein interaction 
network of 217 PPARγ predicted gene targets, glycolytic enzymes PGK1 and PKM2 
were chosen for the functional validation in human adenocarcinomas, MDA-MB-231 
and MCF-7. PGK1 and PKM2, PPARγ regulation were functionally validated by 
PPARγ natural ligand, 15d-PGJ2. It was observed that PPARγ activation by 15d-
PGJ2 led to significant down regulation of glycolytic enzymes-PGK1 and PKM2. 
Since these glycolytic enzymes are involved in ATP synthesis, their down regulation 
resulted in decrease in level of cytoplasmic and mitochondrial ATP. It was also 
observed that PPARγ activation also induced caspase dependent apoptosis, which 
were evident by activation of caspase-8 and loss of mitochondrial membrane 
potential in MDA-MB-231 and MCF-7. Based upon this work I conclude that the 
glycolytic enzymes, PGK1 and PKM2 are potential therapeutic transcriptional targets 
of PPARγ involved in breast cancer pathophysiology.  
      In chapter 3, I identified HHQ as a novel ligand for PPARγ. I confrmed by 
docking procedures that HHQ docks to the PPARγ ligand binding domain and 
compared the docking parameters (ligand binding propertis) with the standard 
PPARγ ligand rosiglitazone. The rerank scores and the hydrogen bond energy values 
for the Rosi- glitazone and HHQ were found to be -122.433, -33.3562 and 5.487 
kcal/mol, -9.460 kcal/mol respectively. In addition Rosiglitazone formed 3 hydrogen 
bonds (Gln286, His449, Ser289) and HHQ forms 5 hydrogen bonds (Gln286, 
His449, Tyr473, Ser289, His323) with ligand binding domain of PPARγ. Additional 
hydrogen bond between HHQ and ligand binding domain of PPARγ indicates 
increased specificity of interaction, which is a fundamental aspect of molecular 
recognition.  Once the docking was confirmed, HHQ then was functionally validated 
with identified PPARγ transcriptional targets, PGK1 and PKM2 in human breast 
adenocarcinoma, MDA-MB-231 and MCF-7. It was found that HHQ induced 
activation of PPARγ down regulated PGK1 and PKM2 expressions significantly.  
Furthermore HHQ also induced caspase dependent apoptosis, which were quite 
evident with activation of caspase-8, increased bax levels, increase in ROS level and 
loss of mitochondrial membrane potential.   Based upon this work I conclude that 
coffee component HHQ is a potential PPARγ ligand and may have potential 
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implication in breast cancer therapeutics. 
       My results have established previously unknown novel crosslink between 
PPARγ, glycolysis, HHQ and breast cancer thereby adding a new dimension to 
therapeutic potential of PPARγ ligands/activators. Although the exact mechanism 
remains unclear and further studies are still needed to clarify the potential role and 
molecular basis of action of PPARγ in breast carcinogenesis, my investigation open a 
new direction for development of novel therapeutic method by targeting PGK1 and 
PKM2 and use of PPARγ ligands/activators in breast cancer therapy.  
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5.2 SUMMARY 
        With increase in complications in treatment of breast cancer, currently, target 
therapies involving modulation of transcriptional targets are become quite popular 
to overcome the adverse effects of cancer therapy and drug resistance. 
Transcriptional factors control gene expression patterns resulting in tumor 
formation and progression as well as metastasis thereby playing critical roles in 
tumorigenesis.  These can be used as molecular therapeutic tools in cancer 
development and progression to regulate transcriptional levels of genes associated 
with disease, verify gene function and to validate target genes for drug design. 
     This research was completely based on the molecularly targeted cancer 
therapeutics. I examine the efforts to specifically target the transcription factors for 
therapeutical interference in cancer development and progression in vitro.  
Below are the summarized results of the research. 
1. I established previously unknown novel crosslink between PPARγ and  
glycolysis via PGK1 and PKM2.  
2. I found out that by targeting PGK1 and PKM2, apoptosis is induced in human 
breast adenocarcinomas.  
3. I also identified novel PPARγ ligand-coffee component HHQ.  
This report also established the unknown link between coffee and breast cancer.  
These findings add a new dimension to therapeutic potential of PPARγ 
ligands/activators and increase the understanding of molecular mechanisms by 
which PPARγ regulates disease targets specifically in breast cancer.  
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5.3  FUTURE DIRECTIONS 
     Cancer therapy involving targeting specific proteins such as transcriptional 
factors, which may have important role in tumorigenesis, could overcome the 
limitations of other cancer therapies such as surgery, chemotherapy, radiation 
therapy and endocrine therapy.  One such popular transcriptional factor is PPARγ. It 
is prudent to note that PPARγ is overexpressed in many cancers including breast 
cancer indicating its importance in tumor development and progression. Taking 
advantage of its overexpression and prudent role in expression of many genes 
required for cell survival these transcriptional targets could serve as a potential 
molecular therapeutics targets in cancer.  
     Epidemiologic evidence suggests that people with diabetes are at significantly 
higher risk for many forms of cancer including breast cancer [219-221]. Obesity has 
also been reported as a risk factor for breast cancer and type- 2 diabetes [222]. The 
possible association could be due to link between diabetes and cancer in metabolic 
syndrome. PPARγ agonist are commonly used to treat patients with type 2 diabetes 
who share metabolic abnormalities, act as insulin sensitizers and mediate in vitro and 
in vivo pleiotropic anticancer effects, suggesting PPARγ as the possible link between 
these diseases [223].  
     Computational analyses by us and generation of gene-disease network suggests 
that PPARγ is implicated in pathology of several diseases including cancer, diabetes, 
and obesity (Figure 5-1) [224]. These results are in accordance with several isolated 
reports on their involvement in individual disorders. These computational findings 
may open new doors to using PPARγ as a therapeutic target for multiple diseases.  
      In addition with extension to our previous findings it would be interesting to see 
the mechanism of cell death and anti-metastatic effect of HHQ in in vivo and in vivo 
cancer models. These finding may open a new direction for development of PPARγ 
ligand - HHQ in breast cancer therapeutics.   
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Figure 4: PPAR gamma disease gene network. Rectangles represent genes and circles represent diseases. Only genes involved in more than
one disease are shown.
IGF system is dysregulated/overactivated (resulting from
receptor and ligand abnormal expression) in a variety of
human malignancies. It has also been shown that a high level
of circulating insulin (hyperinsulinemia) is associatedwith an
increased risk for a number of malignancies [94]. Moreover,
hyperinsulinemia is closely associated with obesity and type
2 diabetes [95]. +iazolidinediones (TZDs) downregulate
both the PI3K and the Ras pathway, which are the two
main signalling pathways downstream receptors of the IGF
system, and they also ameliorate insulin resistance and lower
circulating levels of insulin and free IGF-I [96]. Moreover,
TZDs, and other PPAR-agonists, such as the prostanoid 15d-
PGJ2 [97], induce a variety of favorable changes (growth
arrest, apoptosis, and/or partial redi/erentiation) in several
malignancies, including liposarcoma, and cancers of the
breast, colon, pancreas, and prostate [98–101]. Oxidants and
in2ammatory mediators such as tumour necrosis factor-
alpha (TNF-alpha) activate nuclear factor kappa B (NF-
kappaB) and activator protein-1 (AP-1) transcription factors,
and enhance the expression of both proin2ammatory and
protective antioxidant genes in several diseases including
cancer and atherosclerosis [102, 103]. NF-kappaB is reported
to promote breast cancer cell migration and metastasis by
inducing the expression of the chemokine receptor CXCR4
[104]. Also, NF-kappaB regulates the expression of a large
number of genes, including growth factors, proin2ammatory
cytokines (e.g., TNFa, IL-6, and IL-1b), adhesion molecules
(e.g., VCAM-1, P-selectin), and others such as iNOS and
COX-2 [105]. PPAR activation by agonists is reported to reg-
ulate in2ammatory responses [106], cell proliferation and dif-
ferentiation, and apoptosis [107]. PPAR훾 regulates expression
(transcriptional level) of proin2ammatory mediators such as
inhibitor nuclear factor-휅B (NF-kappaB), signal transducers
and activators of transcription (STAT)-1, and activating
protein-1 (AP-1) activating signals [108]. Since, both PPAR훾
activator and NF-KappaB are transcription factors, it was
proposed that PPAR훾 likely acts through physical interaction
withNF-kappaB, resulting in the inhibition of transcriptional
activation [109]. +e suppressive action of PPAR훾 on NF-
kappaB was suggested to be related to its competition for
limited availability of transcriptional coactivators [110] and it
was suggested that due to this limitation of cofactors, neither
NF-kappaB nor AP-1 could activate their target genes (e.g.,
iNOS or TNFa) [111]. +us, transrepression appears to be
one viable mechanism by which PPAR훾 activators exert their
anti-in2ammatory e/ects on age-induced in2ammation and
oxidative stress via the downregulation of NF-kappaB.
+us, PPAR gamma agonists have been reported as
new and potentially e3cacious treatment of in2ammation,
diabetes, obesity, cancer, AD, and schizophrenia [112].+e use
 
 
Figure 5-1: PPAR gamma disease gene network. Rectangles represent genes and circles 
re rese t diseases. Only genes involved in more than one disease are shown. 
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